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Chapter 1
Introduction
1 Context
The present study has been developed within the study plan of the Master’s
degree in Statistics and Operations Research imparted by Universitat Politècnica
de Catalunya (UPC) and Universitat de Barcelona (UB). The investigation was
developed in the Epidemiology Unit of the Cardiology Service (UESCA) located in
Vall d’Hebron Hospital (Barcelona) within the Vall d’Hebron Research Institute
(VHIR). The main investigator of UESCA is Dr. Ignacio Ferreira and he has
been one of the guides and drivers of the project as well as Josep Ramon Marsal,
Aida Ribera and Purificación Cascant. This team has published several articles in
scientific journals and also gives conferences and lectures addressed to statistical and
clinical professionals. The current studies that UESCA are implementing are related
to survival analysis and multi-state Markov modeling for the cost-eﬀectiveness
problem.
Special mention deserves the director of this project Guadalupe Gómez who without
her guidance and clarifications this project would not have been possible.
2 State of the art
This study is divided into two diﬀerentiated parts. The first part will be devoted
to detect risk factors for the non-adherence to treatment in patients with ischemic
cardiopathology. The second part will be devoted to build a methodology for
estimating survival functions when covariate membership is not defined at baseline
but during the follow-up of the study. This latter part will conclude with the
application of this methodology to an available data set.
5
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2.1 Non-adherence model
Health-care centers aim to reduce morbidity and prevent further hospitalization in
patients with chronic heart diseases [1]. Adherence varies between primary and
secondary prevention12 and it takes place in the 50% and 66% of the patients,
respectively [2]. The aim of this part of the study is to describe the non-adherence
to treatment in chronic heart diseases patients.
Adherence to treatment is decisive at the time of overcoming a disease or enhancing
the patient quality of life, however there are several factors that lead to the
non-adherence of a patient. The believe that a patient is solely responsible of
being non-adherent is a misinterpretation of the problematic. In fact adherence
to treatment is a transversal phenomenon determined by the role of five diﬀerent
factors [3, 4]:
Social-economic factors Poor socio-economic status, poverty, illiteracy, low
level of education, unemployment or family disfunction are some of the risk factors
for the non-adherence to treatment. Also the cost of medication and the distance
between place of residence and the hospital aﬀects the adherence.
Patient-related factors Personal feelings such as having sense of enhancement
or severity of the symptoms can also have an eﬀect on adherence. Lifestyles and
the capability of self-management of their own treatments are also important.
Therapy-related factors Complexity of medical regimen as well as the number
of daily doses or duration of the therapy can influence adherence.
Clinical-related factors The fact of presenting several co-morbilities seems
to be a diﬀerential risk factor for the non-adherence. Focusing on cardiology,
approximately one third of patients with a history of myocardial infarction and
one half without are non-adherent to eﬀective cardiovascular preventive treatment
[2]. Psychological diseases such depression may also interfere negatively in the
compliance of a treatment.
Health system factors Lack of communication between patients and doctors
could modify the adherence behavior. Some studies indicates that health system
should increase awareness on the completely compilation of the prescribed treatment
in order to maximize the enhancement of the disease. Also a collaborative patient-
doctor partnership helps to improve adherence to treatment [5].
This first part of the study will be focused on the detection of social-economic
and clinical-related risk factors that can aﬀect to the adherence in patients with
1Primary prevention aims to prevent disease or injury before it ever occurs.
2Secondary prevention aims to reduce the impact of a disease or injury that has already
occurred.
Chapter 1. Introduction 7
ischemic cardiopathology. First of all the non-adherence concept will be defined
and subsequently a description of the data available will be carried out. Following
this, the methodology for building and validating the model will be summarized
and finally the non-adherence model will be set and discussed.
2.2 Landmark analysis. A survival study
The landmark method was introduced in 1983, in the first year of the Journal
of Clinical Oncology (JCO) by Anderson et al, in an article addressing the issue
of bias in the analysis of survival of ”responders” and ”non-responders” [6]. This
method enables to correct the bias in the estimation of a survival function when
membership status is not determined at baseline but later during the follow-up.
This situation is not unusual in clinical trials: If in a randomized clinical trial a
patient is assigned to treatment A and during the study the physician realizes
that this treatment is worsening his or her health and that probably the same
patient would improve in treatment B, the physician could switch this patient from
treatment A to B.
Inadequate statistical comparisons of survival distributions of ”responders” and
”non-responders” were identified in approximately 20% of phase II and phase III
clinical trials in a survey of articles that appeared from 1979 to 1981 in Cancer and
Cancer Treatment Reports [6, 8]. Landmark methodology is simple in its execution
and can be described graphically as it is done with Kaplan & Meier estimates.
Nowadays the interest in landmark methodology is growing and it appears to be
of particular interest in cardiovascular research. The purpose of this part of the
study is to build this methodology under diﬀerent restrictions and also to report
and discuss the results obtained with the data set available.
3 Project structure
This project is structured as follows:
Chapter 2 will present the motivation and objectives of the project as well as the
structure of the data exploited. It also will content a brief explanation of the data
management performed before starting the analysis. Chapter 3 will be devoted to
expose the data analysis and the building process for the non-adherence model.
At the end of this chapter results will be presented and briefs conclusions will
be discussed. In Chapter 4 it will be built, achieved and developed the survival
estimator within the landmark framework. This estimator will be obtained under
diﬀerent restrictions. Chapter 5 will present the results achieved applying the
landmark methodology. This chapter will also contain a comparison of the results
obtained with this method and the ones achieved by Kaplan & Meier. In Chapter 6
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an overall view of the results reached during the study will be presented and general
conclusions will be discussed. The study will conclude analyzing its limitations and
the possibilities on further research that it enables for upcoming studies.

Chapter 2
Motivation and data
1 Motivating data
The data in study comes from the Adherence to Treatment of Coronary
Patients After Catheterization With Drug Eluting Stent Implantation
[9] study. The main aim of the study was to find predictors of antiplatelet therapy
discontinuation (ATD). The study involved 29 participating hospitals in Spain and
all patients who received at least one drug eluting stent between 28 January and 28
April were recruited by clinical investigators in each center. ATD could be assessed
in 1622 candidates for follow-up.
It was a prospective study with 3-, 6-, 9- and 12- month follow-up. Study variables
included cardiovascular information and those patients who signed informed consent
documents were interviewed to record social class, educational level and depression
screen score PHQ91 (Patient Health Questionnaire 915) [10]. Patients who consent
it were interviewed by phone at 3, 6, 9 and 12 months using a questionnaire to
ascertain vital status, current medications, hospital readmissions and medications
temporary or permanently interrupted since the previous call. The reasons about
medical interruptions were collected diﬀerentiating between a justified interruption
(medical prescription) or non justified interruption.
At the beginning of the study patients started with one, two or three pills; all of
them combination of three distinct drugs: Angiotensin-converting-enzime inhibitor
(ACE inhibitor), beta-blockers and statins. ACE inhibitors and beta-blockers
are two pharmacological families which are used to control arterial hypertension.
Several studies demonstrate that the use of ACE inhibitors implies a gain in lives
saved [11]. On the other hand, statins is a pharmacological drug for reducing
the total amount of cholesterol especially the Low Density Lipoprotein (LDL)
proportion. Several studies claim that taking statins reduces the risk of suﬀering
a cardiovascular event. Concretely, the fact of taking statins reduces between 4%
1PHQ9 is a test which scores the level of depression in patients recruited in clinical trials.
10
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and 7% the probability of having a heart attack or stroke in patients with high
levels of cholesterol and with cardiovascular disease clinical history [12].
2 Data bases and data management
Let τ be the duration of the follow-up of the study and let tk be the kth time when
the phone call was performed, k = 1, ..., 4. Each tk corresponds to the 3rd, 6th, 9th,
and the 12th month of the study, respectively. The performance of the four calls
divides the follow-up of the study into four time intervals, Ik = (tk−1, tk]. Each
of the four tk stored if the treatment performed for the patient during Ik was to
take none, one, two or three pills. Non-adherence is not greatly influenced by the
class of drug prescribed [2], so information about the combination of pills was not
considered.
We will denominate Zi(0) as the number of pills prescribed to the ith patient at
the beginning of the study. The object of the study will be the the number of pills
taken for each patient in each Ik and we will refer to it as Zi(tk).
t = 0
Zi(0)
t1
Zi(t1)
t2
Zi(t2)
t3
Zi(t3)
t4
Zi(t4)
τ
Figure 2.1: Timeline for the ith patient. Patients at t = 0 were prescribed with
Z(0) ∈ {1, 2, 3} pills, however during the follow-up of the study they could change
this number of pills. This information is stored in the variable Zi(tk) ∈ {0, 1, 2, 3},
k = 1, ..., 4.
The data in study consists on two distinct data bases:
Baseline information data base This data base stores clinical and socio-
demographic baseline variables and it consists on 1881 patients. The median of the
age distribution is 64 years and most of the patients in the sample are males (79%).
Event information data base This data set stores patients, from the baseline
data base, that suﬀered at least one of these events: death (n = 55), stroke (n = 12)
and acute coronary syndrome (n = 85). Patients could suﬀer more than a single
event and this information was also stored. It consists on 135 patients whose median
age is 71 years and most of them are males (71%).
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t = 0
Zi(0)
S t1
Zi(t1)
t2
Zi(t2)
D τ
t = 0
Zi(0)
t1
Zi(t1)
t2
Zi(t2)
t3
Zi(t3)
H t4
Zi(t4)
τ
t = 0
Zi(0)
S
Figure 2.2: Three examples of event profile stored in the event data set. All patients
stored in this data base suﬀered at least one of three events: death (D), stroke (S)
or acute coronary syndrome (H ). If a patient suﬀered H or S he or she continued
in the follow-up of the study (second example). Also the censoring pattern showed
in the third example occurs although it is a marginal situation.
For the purpose of this study some information was removed in order to eliminate
heterogeneity and variability not covered by the variables in the study. Figure 2.3
shows a flux diagram with these removals.
Figure 2.3: Flux diagram showing the dropping of some information stored in the
data set. Patients starting with one pill and patients not completely followed were
withdrawn.
Patients who started with one single pill, Zi(0) = 1, were removed of both data
sets. This part of the sample (9.7% of the total amount of patients) were patients
with several acute clinical complications. No information about these complications
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was stored in any variable so the fact of maintaining these patients would have
been an addition of variability not covered for any variable. Patients not completely
followed (18.8% of the total amount of patients) are heterogeneous in the sense
of events suﬀered. Missing information of Z(tk) was mainly given by the fact of
having suﬀered an event but also due to unknown causes. Due to the fact that we
were interested in baseline information, event information could not be taken into
account for the non-adherence study so these patients were withdrawn from the
baseline data set.
At the end of this process the baseline data set stored 1344 patients and the event
data base had 128 patients under risk at t = 0. The set of baseline variables consists
on 35 clinical and socio-demographic variables. These are the following:
1. Clinical variables
Dichotomous variables: Yes, no
Stent with oﬀ-label indications
Ejection fraction < 45%
Acute coronary syndrome
Heart failure
Stroke
Chronic obstructive pulmonary disease
Renal chronic disease
Previous hemorrhagic stroke
Previous major surgery
Cancer
Long term anti-thrombotic therapy before admission
Long term anticoagulants before admission
Pacemaker
Atrial fibrillation
Previous acute myocardial infarction
Previous coronary artery bypass grafting
Previous percutaneous transcatheter coronary angiography
Hypercholesterolemia
Hypertension
Diabetes
Arterial Obstruction
Categorical variables
Medical covering: Non-pensioner, pensioner, payment
Number of extra pills2: 0, 1-2, 3-9 pills
2Number of pills added to the number of pills inherent at the study due to co-morbilities.
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2. Socio-demographic variables
Dichotomous variables: Yes, no
Gender: Female, male
Smoking
University graduate
Immigrant
PHQ9 3 ≥ 10
Living alone
Patient in a clinical trial
Two or more medical visits during the last year
Categorical variables
Familiar situation: Couple, widowed, other situations
Professional situation: Active, retired, unemployed, other
Educational level: Non-school graduate, school graduate, higher education
Continuous variable
Age
At the end of this data management the available information for the study is:
Zi(0) ∈ {2, 3} pills , Zi(tk) ∈ {0, 1, 2, 3} pills (2.1)
for the ith patient and k = 1, ..., 4.
3PHQ9 score higher or equal ten describes moderate and high levels of depression.

Chapter 3
The non-adherence model
In this chapter a model for non-adherence to treatment for patients with ischemic
heart disease is going to be built. For the purpose of this part of the study we have
worked with the baseline data set. Let i = 1, ..., N be the patient index and let
j = 2, 3 be both values that Zi(0) can take for the ith patient. Being Zi(tk) the
random variable that stores the number of pills taken during Ik we define the total
number of pills taken for the ith patient during the study as follows
Zi =
4￿
k=1
Zi(tk). (3.1)
We will refer to this variable as the score for the ith patient.
A patient has fulfilled the treatment if he or she has maintained in each Ik the number
of pills that were prescribed al t = 0. So the ideal score would be accomplished
with Zideal,i = 4 · Zi(0) = 4j pills.
The concept of adherence to treatment is controversial and there is no a common
agreement [7]. For the purpose of this work we state that a patient is adherent to
treatment if he or she has taken, at least, 75% of the fulfilled treatment. Defining,
Si =
Zi
4j · 100 i = 1, ..., N ; j = 2, 3 (3.2)
as the percentage of the fulfilling for the ith patient, we can define the non-adherence
to treatment as a dichotomous variable
Yi =
￿
0 if Si ≥ 75%
1 if Si < 75%
for the ith patient.
16
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1 Descriptive analysis
The main aim of this section is to describe firstly the non-adherence variable, Yi,
for those patients starting with two pills, Z(0) = 2, and those starting with three
Z(0) = 3. Following this we present a comparative analysis of the Yi distribution
between the levels of the baseline variables.
Non-adherence variable Table 3.1 shows how the non-adherence variable is
distributed within the Z(0) levels and Figure 3.1 describes the Zi random variable.
Z(0) = 2 Z(0) = 3
Y = 0 Y = 1 Y = 0 Y = 1
n(%) 621 (92.8%) 48 (7.2%) 498 (73.8%) 177 (26.2%)
Table 3.1: Distribution of the non-adherence variable within both levels of Z(0).
Also the percentage within each level is computed.
0 100 300 500
0
2
4
6
8
10
12
Z0 = 2
Patient 
 N=669
Z i
0 100 300 500 700
0
2
4
6
8
10
12
Z0 = 3
Patient 
 N=675
Z i
Figure 3.1: Plot of Zi within both levels of Z(0). Medians of the distributions are
represented as a red dashed lines and their values are 8 and 12, respectively.
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Most of the sample is adherent to the treatment and this fact is more evident
in patients starting with two pills. The value of the medians for Z(0) = 2 and
Z(0) = 3 are 8 and 12, respectively. Notice that Z(0) = 2 sample could exceed
its ideal score. This happens due to the fact that this part of the sample could
take three pills in some Ik if for medical prescription was needed. None of the
patients starting with three pills could exceed this number in any point of the
study, they could either maintain it or decrease it (see expression (2.1), in Chapter
2). This circumstance explains the fact that patients starting with two pills are
more adherent to treatment than the ones starting with three pills.
Table 3.2 presents the number of patients who, starting with two pills, reached or
surpassed its ideal score.
Zi 8 9 10 11 12 Total
n(%) 439 (75.9%) 11 (2.0%) 12 (2.0%) 30 (5.2%) 86 (14.9%) 578
Table 3.2: Distribution of the Zi scores for the Z(0) = 2 sample in the case of
reaching or surpassing the ideal score. 578 patients starting with two pills reached
or surpassed its ideal score. Percentages are computed among these 578 patients.
The most frequent of the highest scores is the one which corresponds to the fulfilled
treatment (75.9%). Noteworthy is the percentage of patients that reached the
maximum score achievable in the study (14.9%). This score was only achievable if
a patient took three pills in each one of the Ik, k = 1, ...4. This fact drives us to
the conclusion that these patients were classified in the Z(0) = 2 group but before
t1 they switch to Z = 3 and they maintained the treatment until t4. This part of
the sample corresponds to the 13% of the Z(0) = 2 sample.
Comparative analysis Results will be presented separately for the dichotomous
and categorical variables. Dichotomous variables will also be divided into socio-
demographic and clinical variables. The hypothesis of independence between the
non-adherence variable and the variables of the study will be checked via the
chi-square test. If population in some cells of the contingency table is less than
five, the test applied will be the Fisher’s exact test. For the dichotomous variables
the number of valid cases N 1 will be reported. This table will also contain the
number of cases with the variable equal ”yes” with the percentage that this part of
the sample represents within the variable, n(%). For the categorical variables the
percentage of non-adherent patients within each level of the variables is computed.
For both tables the significance of the independence test will be reported.
1number of patients that have information of this variable.
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Y = 1 Y = 0
Socio− demographic
V ariables N n(%) N n(%) p− value
Age 225 63.8 1118 64.1 0.787
Gender (women) 225 53 (23.6) 1119 227 (20.3%) 0.312
Smoking 225 48 (21.3%) 1119 254 (22.7%) 0.719
University graduate 225 201 (89.3%) 1119 962 (85.9%) 0.214
Immigrant 225 7 (3.1%) 1119 31 (2.8%) 0.951
PHQ9≥ 10 224 39 (17.4%) 1095 114 (10.4%) 0.004
Living alone 225 21 (9.3) 1119 111 (9.9%) 0.883
Clinical trial 225 39 (17.3%) 1117 131 (11.7 %) 0.028
Medical visits/year ≥ 2 221 41 (18.6%) 1090 189 (17.3%) 0.497
Clinical variables N n(%) N n(%) p− value
Stent with oﬄabel indications 225 146 (64.9%) 1119 721 (64.4%) 0.957
Ejection fraction < 45% 171 34 (19.9%) 837 117 (14%) 0.064
Acute Coronary Sindrome 225 142 (63.1%) 1119 664 (59.3%) 0.327
Heart failure 225 24 (10.7%) 1119 59 (5.3%) 0.004
Stroke 225 9 (4%) 1119 58 (5.2%) 0.564
Chronic obstructive pulmonary disease 225 29 (12.9%) 1119 100 (8.9%) 0.087
Renal chronic disease 225 16 (7.1%) 1119 66 (5.9%) 0.589
Previous hemorrhagic stroke 225 6 (2.7%) 1119 23 (2.1%) 0.613
Previous major surgery 225 62 (27.6%) 1119 338 (30.2%) 0.476
Cancer 225 4 (1.8%) 1119 19 (1.7%) 1.000
Long term AT2before admission 225 117 (52%) 1116 595 (53.3%) 0.774
Long term AC3before admission 223 13 (5.8%) 1112 39 (3.5%) 0.148
Pacemaker 225 2 (0.9%) 1119 14 (1.3%) 1.000
Atrial fibrillation 225 17 (7.6%) 1119 35 (3.1%) 0.003
Previous AMI4 225 66 (29.3%) 1119 321 (28.7%) 0.909
Previous CABG5 225 60 (26.7%) 1119 317 (28.3%) 0.670
Previous PTCA6 225 20 (8.9%) 1119 93 (8.3%) 0.878
Hypercholesterolemia 225 134 (59.6%) 1119 711 (63.5%) 0.292
Hypertension 225 150 (66.7%) 1119 747 (66.8%) 1.000
Diabetes 225 85 (37.8%) 1119 408 (36.5%) 0.766
Arterial Obstruction 225 27 (12%) 1119 139 (12.4%) 0.949
2 Antithrombotic therapy, 3 Anticoagulants, 4 Acute myocardial infarction, 5 Coronary artery
bypass grafting, 6 Percutaneous transcatheter coronary angigraphy
Table 3.3: Dichotomous variables of the study. Valid cases are reported, N , and
also the number of cases when the variable is equal one with the percentage of the
population that it represents, n(%). The p-value of the chi-square statistic or the
Fisher’s Test is also reported. In bold, variables with the lowest p-values.
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Y = 0 Y = 1 Percentage
Familiar situation
Couple 879 179 16.9%
Widowed 106 16 13.1%
Other 100 24 19.4%
p-value = 0.4116
Medical covering
Non pensioner 384 79 17.1%
Pensioner 667 141 17.5%
Payment 45 2 4.3%
p-value=0.06248
Number of extra pills
0 pills 100 25 20%
1 or 2 pills 674 136 16.8%
{3, 9} pills 345 64 15.6%
p-value = 0.5209
Professional situation
Active 383 72 15.8%
Retired 595 121 16.9%
Unemployed 26 8 23.5%
Other 107 23 17.7%
p-value = 0.6842
Educational level
Non School Graduate 302 71 19%
School Graduate 634 128 16.8%
Higher education 158 24 13.2%
p-value = 0.2234
Table 3.4: Distribution of the categorial variables of the study. The percentage
of patients who are non-adherent within each level of the variable is computed.
Also the p-value of the chi-square statistic or the Fisher’s Test is reported. In bold,
variables with the lowest p-values.
The results of this initial exploratory analysis lead to similar results presented
in the literature [3, 4]. The fact of presenting co-morbilities and also the fact of
presenting a severe or moderate level of depression could aﬀect the adherence to
treatment (PHQ9≥ 10, p = 0.004). The fact of having added cardiac diseases seems
to have an impact in the compliance to treatment (Heart failure p = 0.004, Atrial
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fibrillation p = 0.003).
2 Methodology
We fit a logistic regression to the non-adherence variable, Yi, in order to find the
predictors for this variable [13, 14].
Let Yi be the dichotomous outcome of interest for the ith patient, i = 1, ..., N .
And let X1, X2, ...,Xp be fixed covariates, that is explanatory variables collected
at the beginning of the study. The set of these covariates for the ith patient is
a p-dimensional vector, xi = (x1i, x2i, ..., xpi), and we will refer to it as the ith
patient profile. The data D collected consists on,
D = {(x1, y1), (x2, y2), ...., (xN , yN )}, xi ∈ Rp, yi ∈ {0, 1}. (3.3)
Observations Yi are a random sample from the population and are independent
variables and identically distributed. Yi follows a Bernoulli distribution,
Yi ∼ Bernoulli(pi), i = 1, .., N (3.4)
with an unknown parameter
pi = P (Yi = 1|xi) pi ∈ [0, 1]. (3.5)
Within the generalized linear model framework the expected value of the outcome
is modeled by a g(·) link function, E(Yi) = g−1(βT · xi). When the outcome of
interest follows a Bernoulli distribution the g−1(·) is the logistic function, σ(·), so
the probability of the outcome can be modeled as
E(Yi) = pi = σ(βT · xi) = 11 + e−βT ·xi , σ(·) ∈ [0, 1]. (3.6)
where β = (β1, ....,βp) are parameters to be estimated. The link function is the
logit function. Therefore, the logistic regression becomes,
log
￿
pi
1− pi
￿
= β0 +
p￿
j=1
βj · xj , i = 1, ..., N. (3.7)
2.1 Model building
In what follows the main steps followed to build the model are sketched.
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i) Univariate logistic regression.
For each one of the variables X1, X2, ...,Xp we built,
log
￿
pj
1− pj
￿
= β0j + βj ·Xj , pj = P (Yi = 1|Xj = xj) (3.8)
for j = 1, ..., p. Those variables with a p-value p ≤ 0.2 are taken into account
for the next step. Although these variables are not statistically significant (with
α = 0.05), these variables are the candidates of becoming statistically relevant
in the multivariate analysis due to a possible readjustment of information [14].
ii) Multivariate logistic regression.
For the m (m < p) variables selected in the previous step we built the following
multivariate model,
log
￿
pi
1− pi
￿
= β0 +
m￿
j=1
βj ·Xj , p = P (Yi = 1|x￿i) (3.9)
where x￿i = (x1i, x2i, ..., xmi), m < p.
iii) Variable withdrawal.
From the model in the previous step, the variable with the largest p-value is
removed from the model. This step is repeated until the model contains only
covariates with p-values p ≤ 0.05.
iv) Variable reintroduction.
Step by step each variable in the study is introduced in the model achieved
in the previous step. We proceed like this to check that none of the variables
dismissed until this step stores information statistically significant. The final
multivariate model contains k ≤ p covariates with p-values p ≤ 0.05.
The stability of the final multivariate model can be examined as follows:
• Estimations of the parameters in the multivariate final model should be
similar to the estimations in the univariate model,
βˆj,multi. ≈ βˆj,univ.; j = 1, ..., k. (3.10)
If this does not take place it could mean that some variables in the model are
correlated. Therefore, interpretations of the model can be incorrect due to the
fact that ￿βj is interacting with the information stored in other variable of the
model. A possible solution to overcome this problem might be to withdraw one
of the correlated covariates and check the model performance (see subsection
2.2) and proceed analogously with the other correlated covariate.
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• Standard errors should present low values and estimations should present
narrow confidence intervals.
• The lowest values of deviance and the Akaike information criterion.
Being y = (y1, ..., yN ) the observed outcome vector we define ￿µ = (￿µ1, ..., ￿µN )
as the expected values of the outcome in the current model, ￿µ = E(Yi). The
deviance of a model is defined as
D = −2 · log
￿L(y; y)
L(￿µ; y)
￿
(3.11)
where L(￿µ, y) is the value of the likelihood function in the current model. On
the other hand L(y; y) is the likelihood function of the saturated model. The
saturated model is a model that has as many parameters as data points. As
Hosmer & Lemeshow states ”a simple example of a saturated model is fitting
a linear regression model when there are only two data points” [14], that is
to estimate the intercept and the slope of the linear regression. In fact this
model is the best model achievable with the data available and the response
variable is predicted perfectly, ￿µ = y. We know that L(y; y) ≥ L(￿µ; y) since
the current model is a special case of the saturated model. We would expect
L(y; y) ≈ L(￿µ; y), so the lower the value of the deviance the better the fitting
of the model.
Akaike Information Criterion (AIC) is defined as,
AIC = 2 · (k − L(￿µ; y)) (3.12)
where k is the number of parameters of the model. The better the model
the higher the value of the likelihood function so the lower the value of the
AIC measure the better the model. This measure includes the number of
parameters for avoiding overfitting.
2.2 Model performance properties
After a logistic regression model has been fitted, a global validation of the model
should be performed. There are several ways to assess the performance of a fitted
model but the traditional approach is to report calibration and discrimination. In
this study, the Hosmer & Lemeshow goodness-of-fit test will check the calibration
and the area under the ROC curve (AUC) will test the discriminative ability of
the fitted model.
Calibration explains how eﬀective the model we have is in describing the outcome
variable. On the other hand discrimination checks if patients who have the outcome
of interest have a higher predicted probability than those who do not present the
outcome.
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Hosmer & Lemeshow goodness-of-fit test [14] Hosmer & Lemeshow goodness-
of-fit test checks if a fitted model explains the response of interest.
This test splits the data into two groups: the observed cases and the expected cases
and computes the distance between them. The first step of the test is to cut the
data into G parts as follows. First of all the probability of developing the response
of each one of the patients must be computed. Once this step is done it is necessary
to sort them in increasing order. It is in this moment when the cutting of the data
has to be performed. The number of cuts is conditioned to the number of values
that the estimated probability takes: The more the probability values can take the
more cuts the test allows.
Hosmer & Lemeshow goodness-of-fit statistic HL, is defined as
HL =
G￿
j=1
￿
oj − n￿j · p¯j
￿2
n￿j · p¯j · (1− p¯j)
(3.13)
and follows a Pearson chi-square statistic with G − 2 degrees of freedom, χ2G−2.
The terms of the expression are:
oj : The observed cases with Y = 1 in the jth cut.
n￿j =
n
G− j + 1 , j = 1, ..., G: Number of subjects that are in the G − j + 1
smallest estimated probabilities for the logistic regression. The value of n is the
total number of probabilities computed for the model. For example, n￿1 = n/G is
the subset of patients that are in the group of the smallest estimated probabilities,
the n￿2 = n/(G− 1) are those patients that are in the second smallest estimated
probabilities; and so on.
p¯j : The average estimated probability for the jth group, which is computed as
p¯j =
1
n￿j
n￿j￿
i=1
mi · pˆi (3.14)
where mi is the number of subjects with the same covariate pattern xi. The factor
pˆi is the estimated probability for the ith patient which is in the corresponding n￿j
group.
Due to its construction, this statistic will take low values if the expected cases
are similar to the observed cases in each cut and higher values as the diﬀerences
between them increase. Setting a α significance level if the test drives to a p-value
p > α it would mean that there is no statistical evidence for rejecting H0, that is,
there would be no evidence for thinking that the model is not explaining our data set.
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ROC curve [15] This tool gives an idea on how the model classifies the cases
into the two levels of the response variable. It consists on plotting the sensitivity7
versus one minus the specificity8 of the fitted model while varying the value of
the pˆ discriminator. The most accepted statistic for testing the discrimination of
the logistic regression fitted is the area under the ROC curve or c-statistic which
measures the probability that the predicted probability of outcome is higher for a
case than for a non case. This value also can be understood as the higher the value
of the area, the higher the values of the sensitivity and specificity.
3 Model for the non adherence
The aim of this section is to present the results achieved on the first and on the last
modeling steps sketched in the section before. Results obtained on the middle steps
will not be presented because they are not relevant for the aim of this study. Results
of the univariate analysis for the dichotomous variables are exposed in Table 3.5.
On the other hand, Table 3.6 exposes the results for the categorical variables. In
these tables the p-value reported is the statistical significance of univariate logistic
regression. The significance of the univariate logistic regression will be very similar
to the significance achieved in section 1 when checking the independence between
the non-adherence variable and each of the variables in study. The new contribution
of the following analysis is that now we will know the odds ratio associated to each
variable. Also its confidence interval will be reported (α = 0.05).
A total of eleven covariates are statistically significant using the threshold p ≤ 0.2.
The significance of the clinical trial variable (see Table 3.5) does not have to
be understood as that being enrolled in a clinical trial is a risk factor for the
non-adherence. The reason of this result is that this variable is correlated with
the value of Z(0): Hospitals that included their patients in a clinical trial tended
to allocate them in Z(0) = 3 and, as it is previously explained, this fact has an
influence on being adherent or not. Due to this fact, this variable is not going to
be considered in the multivariate model.
7Sensitivity measures the proportion of actual positive cases (Y = 1) which are correctly
defined as such.
8Specificity measures the proportion of actual negatives cases (Y = 0) which are correctly
defined as such.
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Socio− demographic
variables p− value ￿OR CI,α = 0.05
Age 0.787 0.998 (0.985, 1.011)
Gender 0.312 1.211 (0.855, 1.692)
Smoking 0.719 0.924 (0.646, 1.299)
University Graduate 0.214 1.367 (0.882, 2.203)
Immigrant 0.951 1.127 (0.451, 2.449)
PHQ9≥ 10 0.004 1.814 (1.209, 2.675)
Living alone 0.883 1.070 (0.668, 1.790)
Clinical Trial 0.028 1.578 (1.057, 2.312)
Medical Visits 0.497 1.169 (0.781, 1.711)
Clinical Variables p− value ￿OR CI,α = 0.95
Stent with oﬀ-label indications 0.957 1.020 (0.758, 1.381)
Ejection fraction < 45% 0.064 1.527 (0.989, 2.311)
Acute Coronary Sindrome 0.327 1.172 (0.874, 1.580)
Heart failure 0.004 2.145 (1.283, 3.487)
Stroke 0.564 0.762 (0.348, 1.486)
Chronic obstructive pulmonary disease 0.087 1.508 (0.956, 2.315)
Renal chronic disease 0.589 1.221 (0.672, 2.099)
Previous hemorrhagic stroke 0.613 1.306 (0.478, 3.049)
Previous major surgery 0.476 0.879 (0.635, 1.204)
Cancer 1.000 1.049 (0.302, 2.820)
Long term AT9before admission 0.774 0.949 (0.712, 1.264)
Long term AC10before admission 0.148 1.703 (0.861, 3.163)
Pacemaker 1.000 0.708 (0.111, 2.557)
Atrial fibrillation 0.003 2.531 (1.361, 4.534)
Previous AMI11 0.909 1.032 (0.749, 1.408)
Previous CABG12 0.670 0.920 (0.662, 1.264)
Previous PTCA13 0.878 1.076 (0.633, 1.749)
Hypercholesterolemia 0.292 0.845 (0.632, 1.135)
Hypertension 1.000 0.996 (0.737, 1.355)
Diabetes 0.766 1.058 (0.785, 1.419)
Arterial Obstruction 0.949 0.961 (0.608, 1.470)
9 Antithrombotic therapy, 10 Anticoagulants, 11 Acute myocardial infarction, 12 Coronary artery
bypass grafting, 13 Percutaneous transcatheter coronary angigraphy
Table 3.5: Univariate analysis for the dichotomous variables of the study. The
significance of the univariate logistic regression is presented as well as the marginal
odds ratio. It also is reported its confidence interval with a significance level
α = 0.05. In bold variables with the lowest p-values
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￿OR CI,α = 0.95
Familiar situation
Couple - -
Widowed 0.741 (0.413, 1.245)
Other 1.179 (0.720, 1.863)
p-value = 0.4116
Medical covering
Non pensioner - -
Pensioner 1.028 (0.761, 1.40)
Payment 0.216 (0.035, 0.720)
p-value=0.06248
Number of extra pills
0 pills - -
1 or 2 pills 0.807 (0.501, 1.321)
{3, 9} pills 0.742 (0.449, 1.257)
p-value = 0.5209
Professional situation
Active - -
Retired 1.082 (0.789, 1.493)
Unemployed 1.637 (0.670, 3.611)
Other 1.143 (0.671, 1.891)
p-value = 0.6842
Educational level
Non School Graduate - -
School Graduate 0.859 (0.625, 1.188)
Higher education 0.646 (0.385, 1.053)
p-value = 0.2234
Table 3.6: Univariate analysis for the categorical variables of the study. The
significance of the univariate logistic regression is presented as well as the marginal
odds ratio. It also is reported its confidence interval with a significance level
α = 0.05. In bold variables with the lowest p-values
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The final multivariate model with its estimates is presented in Table 3.7.
V ariables βˆj Std. Error p-value ￿ORj CI,α = 0.05
Intercept -1.681 0.129 < 2 · 10−16 0.186 -
Heart failure 0.569 0.266 0.032 1.767 (1.031,2.938)
PHQ9≥ 10 0.530 0.207 0.010 1.699 (1.122,2.526)
Atrial fibrillation 0.819 0.318 0.010 2.268 (1.190,4.171)
Medical covering14
Pensioner -0.061 0.158 0.701 0.941 (0.692,1.286)
Payment -1.513 0.735 0.039 0.220 (0.035,0.736)
Deviance: 1166.3
AIC: 1178.3
14 reference category non-pensioner
Table 3.7: Estimations of the coeﬃcients and odds ratio with its confidence interval
in the multivariate model. The reference category is not presenting the exposition,
except for the medical covering variable. It also is presented the significance of
each of the levels of the covariates. Null deviance and AIC values are reported at
the end of the table.
The multivariate model maintains the covariates that were statistically significant
in the univariate logistic regression (with α = 0.05). On the other hand, medical
covering variable has been included. This covariate has one of their two levels not
statistically significant for the non-adherence variable. Despite of this fact, this
covariate remained in the model due to the fact that one of its levels is statistically
significant so the variable is clinically meaningful.
4 Results
The fact of presenting heart failure (p = 0.032,￿OR = 1.767) and/or atrial fibrillation
(p = 0.010, ￿OR = 2.268) is a risk factor for the non adherence to treatment. Also
the fact of presenting a moderate/acute grade of depression has an adverse impact
at the time of being adherent (p = 0.010, ￿OR = 1.699). Having a payment medical
covering seems to be a protector factor for the non-adherence in relation to not
being a pensioner (p = 0.039, ￿OR = 0.220).
Regarding to the prerequisites of stability, our model seems to overcome this type
of problematic. The current model is the model that achieved the lowest values of
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deviance (1166.3) and Akaike Information Criterion (1178.3).
Hosmer & Lemeshow test was performed using G = 3 cuts, obtaining a value of
HL = 0.1301 (p-value p = 0.7183 under HL ∼ χ1). Regarding to this, we cannot
reject the null hypothesis that the observed cases are the same that the expected
cases in each one of the three cuts, thereore the calibration of the model is correct.
In Figure 3.2 three diﬀerent plots are presented.
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Figure 3.2: Probabilities estimated (upper-left plot), observed cases versus expected
cases in each of the G = 3 cuts (upper-right plot) and the ROC curve of the model.
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The upper-left plot shows the predicted probabilities that our model computes.
Notice that these probabilities have a discrete range of values, that is they cannot
be described as a continuous variable. This is given by the fact that the covariates
in the model are dichotomous or categorical and this leads to a few number of
combinations of the values of the covariates. Therefore few values of predicted
probabilities are computed. It is due to this fact that the Hosmer & Lemeshow test
only can perform a low value of cuts, in this case G = 3 (see subsection 2.2 in this
chapter).
On the upper-right, a goodness-of-fit plot based on the Hosmer & Lemeshow test
is built by plotting the observed cases versus the expected cases for each of the
G = 3 cuts. A straight line indicates the best behavior of the fitted model. Our
model is well calibrated and observed non-adherent rates match perfectly with the
expected ones in each cut (r2 = 1).
The bottom plot presents the ROC curve of the model. The area under the ROC
curve is not the best expected for a model due to its low value (AUC=0.598). This
value can be understood as that the probability that a predicted probability is
higher for a non adherent than for an adherent is p ≈ 0.6. In other words, our model
is not clearly giving higher non-adherence probability to an actual non-adherent
in comparison to the probabilities that it is giving to an actual adherent patient.
One procedure that can be applied when a model achieves low values of AUC is to
prioritize between specificity or sensitivity.
Table 3.8 presents two confusion matrices built with two consecutive thresholds.
Thresholds between these values do not variate sensitivity and specificity.
Yi = 1 Yi = 0￿Yi = 1 220 1047￿Yi = 0 2 45
sensitivity= 0.991
specificity= 0.041
Yi = 1 Yi = 0￿Yi = 1 128 512￿Yi = 0 94 580
sensitivity= 0.577
specificity= 0.531
Table 3.8: Confusion matrices for the thresholds ￿p = 0.129 and ￿p = 0.150, respec-
tively. Yi and ￿Yi make reference to the actual values of the response variable and
the predicted values under each of both thresholds, respectively. Specificity and
sensitivity for each threshold is presented at the bottom of each confusion matrix.
The objective of this study is to detect those patients that would become non-
adherent so we are interested in reaching high sensitivity values. If we decide to
choose the ￿p = 0.129 threshold we are classifying almost perfectly those patient that
are actual non adherent to the non adherent status (sensitivity= 0.991). However
we are nullifying the capability of the model on classifying those patients that would
become adherent (specificity= 0.041). On the other hand if we decide ￿p = 0.150 as
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a threshold, the model is neither a good non-adherent classifier nor a good adherent
classifier (sensitivity= 0.577, specificity= 0.531).

Chapter 4
Landmark methodology
The landmark methodology is used to estimate, in an unbiased way, the time to
event probabilities stratified by a covariate when group membership is not defined
at baseline but during the follow-up of the study. Let X be the covariate of interest
presenting p diﬀerent levels, j = 1, ..., p. When belonging to the jth group depends
on time, the landmark analysis is an adequate and intuitive technique to estimate
the survival function in each level of the covariate, Sj(t), in t ∈ [0, τ ], being τ the
time of the follow-up of the study. Therefore, this methodology is an approach to
the problem of time depending covariates when the time dependence is an unknown
function.
In this chapter the concept of migration will make reference to the number of
patients moving from one level of X to a diﬀerent level of X taking into account
the sense of these movements. Being j1 and j2 two levels of X, the concept one
sense migration will make reference to the fact that migrations from j1 to j2 will
be allowed but from j2 to j1 will not. On the other hand when talking about two
sense migration we will allow migrations from j1 to j2 as well as from j2 to j1.
The number of pills taken for the ith patient could change during the Ik = (tk−1, tk],
k = 1, ..., 4 time intervals defined in Chapter 2. Recall that the variable which
stores the number of pills taken during Ik is Zi(tk) ∈ {0, 1, 2, 3}, i = 1, ..., N and
k = 1, ..., 4. Being n the individuals under risk at the beginning of the study in
the pooled sample, the variable of interest for the present study, X, will be fact of
taking two or less pills or to take three during Ik,
Xi(tk) =
￿
2 if Zi(tk) ≤ 2
3 if Zi(tk) = 3
for i = 1, ..., n and k = 1, ..., 4.
Let nj and dj be the individuals under risk and the total number of events in
each level of X, j = 2, 3. The potential times until the event of interest E in
each level of X will be denoted as T1, T2, ..., Tnj . Generally right censoring Ci
33
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can happen, i = 1, ..., nj . When censoring is contemplated we observe the pairs
(Y1, δ1), ..., (Ynj , δnj ) where δi = {Ti ≤ Ci}, i = 1, ..., nj .
The first section of the chapter will be devoted to describe the method under the
restriction of one sense migration without allowing censoring [16]. The following
section will develop the method allowing censoring and finally we will extend
it for two sense migration allowing censoring. This chapter will conclude with
a summary of the Fleming & Harrington test family and how the proportional
hazards condition can be checked. If proportional hazards assumption holds, we
will proceed estimating the value of this hazard ratio.
1 One sense migration with no censoring
In this section migrations from X = 2 to X = 3 are allowed during the follow-
up while from X = 3 to X = 2 are not. Migrations occur inside time intervals,
Ik = (tk−1, tk] and it is not known in which precise time they happen, k = 1, ...,K.
Due to this fact, migrations will be counted at the end of the kth interval, that is
in tk. Migrations in this time will be denoted as sk. Being ∆ti the elapsed time
between tk and the time of the first event just after it, we define the kth landmark
point as tk+∆ti, that is the first time with an event after a time where a migration
has occurred.
Times tk will be the same in both levels of X, k = 1, ...,K. However, due to its
definition, landmark points does not necessarily have to coincide in both levels
because ∆ti might not be the same in each level of X.
If no censoring occurs, all patients under risk will experience the event of interest,
therefore nj = dj . Lets consider the order statistic T(1), T(2), ..., T(dj). Just before
T(i) we observe nji patients under risk in the jth group and dji events in T(i),
j = 2, 3 and i = 1, ..., dj .
0 t1 t2 t3 . . . tk
sk ￿= 0
tk +∆ti
. . . tdj τ
Figure 4.1: Timeline with the time events represented, ti, i = 1, ..., dj . Migrations
occur in K diﬀerent times (sk ￿= 0). In tk + ∆ti these migrations have they
repercussion.
For each i the following equalities hold,
for ti = tk +∆ti :
n2i = n2k − d2k − skn3i = n3k − d3k + sk (4.1)
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for ti ∈ (tk +∆ti, tk+1] : nji = nji−1 − dji−1 (4.2)
for k = 1, ...,K and j = 2, 3. For the X = 3 sample, migrations in tk are an
increment of population at the kth landmark point. On the other hand for the
X = 2 sample migrations are treated as censored patients.
1.1 Landmark survival estimator
The estimation of the survival function for X = 3 in the kth landmark point,
S3(tk +∆ti), collects two type of contributions: i) patients that in tk survived in
X = 3 and ii) patients in X = 2 who have survived at tk and have migrated to
X = 3. Figure 4.2 shows an scheme of these contributions.
S3(tk +∆ti)
S3(tk)
S2(tk)
S2(tk +∆ti)S2(tk)
Figure 4.2: Illustration of the tk history contributions to the survival function in
the kth landmark point, Sj(tk +∆ti), k = 1, ...,K and j = 2, 3. Survival for X = 2
does not have incorporations of survived patients coming from X = 3.
For ti−1 < ti :
S3(ti) = P (T > ti|X = 3)
(1)= P (T > ti, X = 3)
P (X = 3)
(2)= P (T > ti−1, T > ti, X = 3)
P (X = 3)
(3)= P (X = 3) · P (T > ti−1|X = 3) · P (T > ti|T > ti−1;X = 3)
P (X = 3)
= P (T > ti|T > ti−1;X = 3) · P (T > ti−1|X = 3)
= P (T > ti|T > ti−1;X = 3) · S(ti−1)
(4.3)
The first equality (1) is set by the definition of conditional probabilities. The
following equality (2) is due to the fact that {T > ti} ⊂ {T > ti−1} ⇒ {T >
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ti} ∩ {T > ti−1} = {T > ti}. Equality (3) is achieved using the theorem of
compound probabilities P (A1 ∩A2 ∩ ...∩An) = P (A1) ·P (A2|A1) ·P (A3|A1 ∩A2) ·
... ·P (An−1|A1 ∩A2 ∩ ...∩An−1) with n = 3 and A1 = {X = 3}, A2 = {T > ti−1}
and A3 = {T > ti}.
Notice that the survival function in equation (4.3) does not have any subindex of
group membership. This is due to the fact that a patient survived in ti−1 that in
ti is in X = 3 can be survived either in X = 2 or X = 3 if ti = tk +∆ti.
The first probability in equation (4.3) is estimated as usual,
￿P (T > ti|T > ti−1;X = 3) = n3i − d3i
n3i
. (4.4)
So,
￿S3(ti) = n3i − d3i
n3i
· ￿S(ti−1). (4.5)
Depending if the estimation is taking place at the kth landmark point or not,￿S(ti−1) collects the two contributions previously exposed or not. So,
￿S3(ti) =

n3i − d3i
n3i
·
￿
n3i − sk
n3i
·￿S3(tk) + sk
n3i
·￿S2(tk)￿ if ti = tk +∆ti
n3i − d3i
n3i
·￿S3(ti−1) if ti ∈ (tk +∆ti, tk+1]
(4.6)
For i = 1, ..., d3 and k = 1, ...,K.
We can rename the terms in equation (4.6) as
αi =
n3i − d3i
n3i
, βk =
n3i − sk
n3i
, 1− βk = sk
n3i
, (4.7)
where,
αi : Proportion of patients in X = 3 who have survived until ti
βk : Proportion of patients that in tk +∆ti are in X = 3 and who have survived
in X = 3 at tk
1 − βk : Proportion of patients that in tk + ∆ti are in X = 3 and who have
survived in X = 2 at tk
Due to the fact that X = 2 does not have incorporations of survived patients
coming from X = 3, the estimator for S2(ti) will be the Kaplan & Meier ∀ti ∈ [0, τ ]:
￿S2(ti) =
1 if ti < T(1)2n2i − d2i
n2i
·￿S2(ti−1) if ti ≥ T(1)2 (4.8)
being T(1)2 the time of the first event in X = 2.
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2 Two sense migration with censoring
Now we shall extend the previous method introducing censoring and following that
we will incorporate the possibility of two sense migrations.
2.1 Censoring
Censoring is also known inside Ik. Due to this fact same considerations assumed for
migrations will be applied for censoring. We define cjk as the number of censored
patients in Ik when belonging to the jth group, k = 1, ...,K and j = 2, 3.
For each i these terms appear in equation (4.1) as,
for ti = tk +∆ti :
n2i = n2k − d2k − c2k − skn3i = n3k − d3k − c3k + sk (4.9)
for k = 1, ...,K. For times ti ∈ (tk + ∆i, tk+1], equation (4.2) does not vary.
Regarding to equation (4.9) censoring has the same sign for both expressions: it
only implies a loss of population under risk. Due to this fact, adding censoring does
not vary the form of the (4.6) and (4.8) estimators.
2.2 Two sense migration
Migrations from X = 2 to X = 3 are allowed as well as from X = 3 to X = 2. Also
censoring during the follow up of the study is contemplated. For each k we define
lk as the migrations from X = 3 to X = 2 occurred in Ik and counted at the end
of tk, k = 1, ...,K.
For each i these terms appear in (4.9) as
for ti = tk +∆ti :
n2i = n2k − d2k − c2k − sk + lkn3i = n3k − d3k − c3k + sk − lk. (4.10)
Again, for times ti ∈ (tk + ∆i, tk+1], equation (4.2) does not vary. Renaming
ωk = sk − lk as the net migration in tk, we can see that while for one group it is
treated as an incorporation of population under risk, for the other risk group it is
treated as a decrement of population under risk for tk +∆ti.
Both survival functions in the kth landmark point, Sj(tk +∆ti), collect two type of
contributions: i) patients who have survived at tk in the jth group and remain in
that group, and ii) patients who have survived at tk in the other group and have
migrated to the jth group. In Figure 4.3 an illustration of these contributions is
Chapter 4. Landmark methodology 38
presented.
S3(tk +∆ti)
S3(tk)
S2(tk)
S2(tk +∆ti)
S3(tk)
S2(tk)
Figure 4.3: Illustration of the contributions of the tk history to the survival function
in the kth landmark point, Sj(tk +∆ti), k = 1, ...,K and j = 2, 3. In this case, the
landmark correction must be also applied to the X = 2 group.
An analogous development followed in equation (4.3) is performed. The estimations
for Sj(ti) in ti ∈ [0, τ ] become,
￿S3(ti) =

n3i − d3i
n3i
·
￿
n3i − sk
n3i
·￿S3(tk) + sk
n3i
·￿S2(tk)￿ if ti = tk +∆ti
n3i − d3i
n3i
·￿S3(ti−1) if ti ∈ (tk +∆ti, tk+1]
(4.11)
￿S2(ti) =

n2i − d2i
n2i
·
￿
n2i − lk
n2i
·￿S2(tk) + lk
n2i
·￿S3(tk)￿ if ti = tk +∆ti
n2i − d2i
n2i
·￿S2(ti−1) if ti ∈ (tk +∆ti, tk+1]
(4.12)
For i = 1, ..., dj , j = 2, 3 and k = 1, ...,K.
For X = 3, estimator (4.6) is obtained again and an analogous estimator is obtained
for X = 2. We rename the terms in equation (4.12)
γi =
n2i − d2i
n2i
, δk =
n2i − lk
n2i
, 1− δk = lk
n2i
, (4.13)
where,
γi : Proportion of patients in X = 2 who have survived until ti
δk : Proportion of patients that in tk +∆ti are in X = 2 and who have survived
in X = 2 at tk
1−δk : Proportion of patients that in tk+∆ti are in X = 2 and who have survived
in X = 3 at tk.
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For the sake of completeness we briefly summarize the Fleming & Harrington family
of tests and the Cox proportional hazards model. These two procedures will be
used to complete our analysis.
3 Fleming & Harrington test family
The aim of this test is to check if diﬀerences between survival curves exist. Contex-
tualizing the notation to our problem the test is formulated as [17, 18]:
H0 : S2(t) = S3(t), t ≤ τ vs. H1 : S2(t) ￿= S3(t), for some t ≤ τ,
where Sj(t) is completely defined within the [0, τ ] time interval, for j = 2, 3.
Let t1 < t2 < ... < tD be the times where an event occurs in the pooled sample. At
time ti we observe dij events out of nij individuals at risk, i = 1, ...,D and j = 2, 3.
Let di = di2 + di3 and ni = ni2 +ni3 be the total number of events and individuals
at risk in the combined sample at time ti, i = 1, ...,D.
If the null hypothesis is true the estimator of the expected hazard rate in the jth
group is the estimated hazard in the pooled sample, ni/di. The test of H0 can be
constructed as a weighted distance between both hazard rates or as a weighted
distance between the observed number of events and the expected number of events
under H0 in the jth sample:
ZW =
￿D
i=1W (ti) ·
￿
di2 − ni2 · dini
￿
￿￿D
i=1W
2(ti) · ni2ni ·
￿
1− ni2ni
￿
· ni−dini−1 · di
(4.14)
When the null hypothesis is true ZW follows a standard normal distribution for
large samples. Weights in equation (4.14) have the form,
W (ti) = ￿S(ti−1)p · ￿1− ￿S(ti−1)￿q , (4.15)
where p ≥ 0 and q ≥ 0. The values of p and q drive to diﬀerent types of tests,
p, q =

p = q = 0 Log-rank test
p = 1, q = 0 Gehan test
p > 0, q = 0 early diﬀerences
p = 0, q > 0 later diﬀerences.
(4.16)
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4 Proportional hazards assumption
4.1 Cox model
Let T be the random variable that indicates the time until the event of interest
and let X = (X1, X2, ...,Xp) be the set of covariates collected at the beginning
of the study. We define Λ0(t) as the baseline cumulative hazard function, that is
the cumulative hazard for a patient with X = 0. We also define the cumulative
hazard function for an individual with profile X, Λ(t|X). The Cox model (1972)
establishes the following multivariate regression between times until the event and
the profile of the patient
Λ(t|X) = Λ0(t) · c(βTX) (4.17)
being β = (β1,β2, ...,βp) a set of parameters to be estimated and c(βTX) a positive
defined function. The traditional choice for this function is the exponential so the
model becomes,
Λ(t|X)
Λ0(t)
= exp(β1 ·X1 + β2 ·X2 + ...βp ·Xp). (4.18)
The right term of the equation only depends on the values of the covariates and
parameters. The Cox model is called the proportional hazard model because the
right term of the equation (4.18) is constant along time.
In the present study only X will be the covariate contemplated in the Cox model.
If we look two individuals with X = 3 and X = 2 respectively the ratio of their
cumulative hazards is
Λ(t|X = 2)
Λ(t|X = 3) = exp(β). (4.19)
4.2 Diagnosis plots and hazard ratio estimation
Several diagnosis plots can be performed to check if proportional hazards assumption
holds for a single covariate in study. In what follows three are presented and two
will allow to estimate the value of the hazard ratio.
i) The first step on the diagnosis is to represent ￿Λ(t|X = 3) and ￿Λ(t|X = 2)
versus time in the same plot. If proportional hazards assumption holds it is
expected to observe a constant distance between estimated functions.
ii) Once proportionality is observed in i) we can assume that exp(β) = k with k
constant. Performing a log-transformation of equation (4.19) we achieve the
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following linear regression,
Λ(t|X = 2)
Λ(t|X = 3) = k ⇒ logΛ(t|X = 2) = log k + logΛ(t|X = 3). (4.20)
Proceeding by this way with our estimates, if linearity holds with a high
r-square (r2), then proportional hazards situation can be assumed. Notice
that ￿β is the estimated parameter of the Cox regresion and it is the estimated
intercept in (4.20). The estimation of the hazard ratio, k, can be reached as
follows, ￿β = log ￿k ⇒ ￿k = e￿β . (4.21)
iii) This procedure consists on plotting the ratio of the cumulative hazards esti-
mates in equidistant points in time, i = 1, ..., l. Hazard ratio in each ti is equal
ki, ￿Λ(ti|X = 2)￿Λ(ti|X = 3) = ￿ki, i = 1, ..., l. (4.22)
If proportional hazards assumption holds, it is expected to visualize a constant
value along time, ￿k1 ≈ ￿k2 ≈ ... ≈ ￿kl and hazard ratio can be estimated as
the median of the ￿ki values, i = 1, ..., l. Once the median is computed, the
estimation of the Cox regression parameter can be reached as done it in
equation (4.21).

Chapter 5
Landmark methodology
application
The motivating data of this master thesis include the following three events: death,
stroke and acute coronary syndrome. We are interested in studying both the times
to death and the time to the first occurring of these three events. See Chapter 2
for a thorough description of the data set. Since we encounter patients changing
from X = 2 to X = 3 as well as from X = 3 to X = 2, we are in a situation of two
sense migration and the methodology developed in Chapter 4 will be used here.
Recall that the data set only stores patients who have had at least one of the three
events previously cited. So when studying death, right censoring will appear (see
the second and the third examples in Figure 2.2 in Chapter 2) but when studying
the first of the events censoring will not occur. The fact of studying only patients
that have suﬀered an event is a limitation of the present study due to the fact that
we are obviating information of the patients that did not suﬀer an event. This will
be discussed in Chapter 6.
We named tk the time where the phone call was performed, k = 1, ..., 4. These
four calls divided the follow-up of the study into four time intervals Ik = (tk−1, tk],
k = 1, ..., 4. These tk correspond to the 3rd, 6th, 9th and 12th month of the study
for k = 1, ..., 4, respectively. Migrations (sk, lk) and censoring (cjk) occurred within
Ik and it is not known in which precise time they happened: a patient could change
the number of pills during Ik but this change was not eﬀective until tk, k = 1, .., 4.
Regarding to this, the present study will have four points where migrations and
censoring occur, tk, and therefore four landmark points will be registered, tk +∆ti
for k = 1, ..., 4 and i = 1, ..., nj .
This chapter is divided into two sections: First section will be devoted to present
the results of the landmark methodology when studying death as outcome and the
second section will have the same purpose but when studying the first occurring
event of the events previously cited. Both sections will contain also a comparison
of these results with the ones obtained obviating migrations, that is, with the
43
Chapter 5. Landmark methodology application 44
estimates obtained applying the Kaplan & Meier estimator. The content of these
sections will be complemented by the computation of the Fleming & Harrington
statistic for the estimates achieved in both methodologies for the variable of interest
X. If the test drives to survival curves statistically diﬀerent we will proceed checking
if proportional hazards assumption holds. If it holds we will proceed computing
the value of the hazards ratio.
1 Survival estimation for death
In Table 5.1 the mortality table for death divided into the Ik time intervals is
presented, k = 1, ..., 4. At the beginning of the study the population under risk in
each level of X was, n2 = 63 and n3 = 65, respectively.
X = 3 X = 2
Ik n3k d3k c3k n2k d2k c2k sk lk
[0, 3] 65 10 3 63 10 2 10 22
(3, 6] 40 2 0 63 5 0 3 9
(6, 9] 32 3 0 64 11 1 5 3
(9, 12] 31 2 0 50 3 0 3 1
(12, 15] 31 3 0 45 6 0 - -
Table 5.1: Population under risk (njk), number of events (djk), censored patients
(cjk) and migrations (sk, lk) within the Ik time intervals, j = 2, 3 and k = 1, ..., 4.
Time intervals expresses trimesters.
The largest amount of migrations took place during the first three months of the
study and migrations from X = 3 to X = 2 doubled migrations from X = 2 to
X = 3. Notice that most of the right censoring pattern is censoring lost to follow-up,
however a total of six patients are dropouts.
Notice that within the landmark framework one can face the situation that, being
ti > ti−1, the population under risk in ti is higher than the population under risk
in ti−1. When studying death as outcome it happens once: just after t2 in the
X = 2 sample where the populations under risk comes from 63 patients and after
it becomes 64.
Table 5.2 presents the quantiles of the survival estimates within boths methodologies.
Figure 5.1 presents the survival estimates (left plots) and plots its quantiles (right
plot). In left plots, landmark points are marked as vertical dashed lines: Green
dashed lines correspond to the four landmark points for the X = 2 sample and
blue dashed lines corresponds to the landmark points for the X = 3 sample. Notice
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that, as it is discussed in the previous chapter, landmark points do not necessarily
have to coincide in both samples.
10% 20% 30% 40% 50%
X = 2
Kaplan & Meier 65 104 240 382 -
Landmark analysis 65 112 240 373 -
X = 3
Kaplan & Meier 58 190 250 459 -
Landmark analysis 58 246 277 459 -
Table 5.2: Quantiles of the survival estimates for both levels of X estimated by
Kaplan & Meier and landmark methodology when studying the death as outcome.
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Figure 5.1: Survival estimates for death estimated by Kaplan & Meier and the
landmark methodology (left plots). Landmark points are marked as vertical dashed
lines. It also are plotted the quantiles per methodology applied and level of X
(right plot).
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Within the landmark methodology distances between curves increase in comparison
to the distance between the estimates obtained within the Kaplan & Meier frame-
work. For X = 2, estimates seem to no vary substantially between methodologies
applied. However for X = 3, after the first landmark point and until the end of
the follow-up, estimates obtained by the landmark methodology are higher than
the ones obtained by Kaplan & Meier. Notice that before the first landmark point,
estimates for both methodologies are the same because no migrations have been
occurred yet.
On the left plots it can be seen the discrepancy in the counting of events between
methodologies per level of X. Table 5.3 presents the total number of events regis-
tered within each methodology in each level of X.
d2 d3 d2 + d3
Kaplan & Meier 29 26 55
Landmark analysis 35 20 55
Table 5.3: Number of events registered in each level of X within both methodologies.
Obviously both methodologies lead to the same total number of events.
Within Kaplan & Meier the number of events per level of X, dj , is conditioned by
the population under risk at the baseline time in each level, nj , with j = 2, 3. Due
to the fact that the landmark methodology updates nj in each landmark point,
the total number of events per level of X varies in relation to the ones observed
applying Kaplan & Meier. Specifically it can be seen that if migrations are not
taken into account there are six events that are counted in X = 3 that actually
belongs to X = 2.
Diﬀerences between survival estimates has been tested for both methodologies. For
both cases was tested the later diﬀerences case (see expression (4.16)). Results of
the Fleming & Harrington test are exposed in Table 5.4.
ZW p-value
Kaplan & Meier 0.6 0.538
Landmark analysis 3.33 0.00044
Table 5.4: Value of the ZW statistic of the Fleming & Harrington test for both
methodologies. Also the p-value of the test is reported. While within the landmark
framework proportional hazards assumption holds, for the Kaplan & Meier estimates
do not.
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Obviating the existence of migrations the Fleming & Harrington test does not
reject the null hypothesis (p-value p = 0.538). However, applying the landmark
analysis, survival curves are statistically diﬀerent with high statistical significance
(p-value p = 0.00044).
If survival estimates are statistically diﬀerent in both samples, hazard rates are
also statistically diﬀerent. Figure 5.2 shows the set of the diagnosis plots presented
in Chapter 4.
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Figure 5.2: Diagnosis plots for the proportional hazards assumption. On the upper-
left plot one can see that proportional hazards seems to take place from the 50th
day until the end of the study. Upper-right plot allows to estimate the hazard ratio
from the linear regression intercept. In the bottom plot hazard ratio is estimated
via the median of the values (red dashed line).
Regarding to the upper-left plot it seems that from the 50th day, distances between
cumulative hazards is constant until the end of the study, therefore proportional
hazards assumption seems to hold for these times.
Chapter 5. Landmark methodology application 48
The linear regression (4.20) performance is represented in the upper-right plot.
Linearity seems to take place with a high r-squared (r2 = 0.9815). The estimated
intercept is ￿β = 0.228, CIα=0.05 = (0.064, 0.393). (5.1)
Using equation (4.21) the estimated hazard ratio becomes,
￿k = 1.256, CIα=0.05 = (1.066, 1.481). (5.2)
The bottom plot allows to estimate the value of the hazards ratio by another
procedure. In this case the median of the values is 1.224 which is inside the
confidence interval computed in equation (5.2).
Finally we conclude that survival estimates for both treatments are statistically
diﬀerent for later times when studying death as outcome. Also the proportional
hazards assumption holds with a hazard ratio,
￿Λ(t|X = 2)￿Λ(t|X = 3) = 1.26, CIα=0.05 = (1.07, 1.5). (5.3)
2 Survival estimation for the first event between
death, stroke and acute coronary syndrome
In this section results will be shown analogously as exposed in the section before.
Table 5.5 presents the information in each of the time intervals of the study.
X = 3 X = 2
Ik n3k d3k n2k d2k sk lk
[0, 3] 65 29 63 23 6 15
(3, 6] 27 9 49 13 2 3
(6, 9] 17 9 37 18 0 2
(9, 12] 10 4 21 13 1 1
(12, 15] 6 6 8 8 - -
Table 5.5: Population under risk (njk), number of events (djk), censored patients
(cjk) and migrations (sk, lk) within the Ik time intervals, j = 2, 3 and k = 1, ..., 4.
Time intervals expresses trimesters.
Most of the migrations happened during the first period of time and were from
X = 3 to X = 2. This sense of migrations almost triples the migrations from
X = 2 to X = 3. Notice that, as it is previously discussed, any type of censoring is
registered in this endpoint of the study.
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Table 5.6 presents the quantiles of the survival estimates. Figure 5.3 presents the
survival estimates achieved within Kaplan & Meier and landmark methodology
(left plots) and plots its quantiles (right plot).
5% 20% 35% 50% 65% 80% 90%
X = 2
Kaplan & Meier 8 56 88 133 237 335 382
Landmark analysis 8 56 88 143 234 285 348
X = 3
Kaplan & Meier 7 36 58 141 234 279 373
Landmark analysis 7 36 58 118 250 359 432
Table 5.6: Quantiles for the survival in both levels of X estimated by Kaplan &
Meier and landmark methodology when studying the first occurring event.
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Figure 5.3: Survival estimates for the first occurring event estimated in both
methodologies (left plots). Landmark points are marked as vertical dashed lines.It
also are plotted the quantiles per methodology applied and level of X (right plot).
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For X = 2 landmark analysis estimates are higher than the ones obtained by
Kaplan & Meier around the median of the distribution. However, after the second
landmark point survival curve decreases faster than the one estimated by Kaplan
& Meier. For X = 3 the behavior is complementary: around the median landmark
analysis estimates are lower than the ones obtained by Kaplan & Meier and for
the later times estimates are higher within the landmark framework.
Another result that landmark results arise is that survival curves cross once during
the follow up of the study while within the Kaplan & Meier estimator curves do
not cross until the very end of the follow-up.
After the third landmark point (percentile ≈ 70%) curves seems to separate one
each other while within the Kaplan & Meier framework this diﬀerences are less
evident and even at the end of the study survival curves cross.
Noteworthy is the change of survival curves direction: Within Kaplan & Meier,￿S2(ti) has a better prognostic than ￿S3(ti) during the whole follow-up of the study.
However, within the landmark analysis and after de second landmark point, this
tendency gets inverted.
Table 5.7 shows the discrepancy on the total number of events per level of X for
each one of the methodologies (also visible on the left plots in Figure 5.3).
d2 d3 d2 + d3
Kaplan & Meier 63 65 128
Landmark analysis 75 53 128
Table 5.7: Total number of events registered in each level of Z within both method-
ologies studied. While within the Kaplan & Meier framework d2 ≈ d3, the landmark
analysis method drives to d2 > d3 situation. Both methodologies must drive to the
same total number of events.
Concretely, if migrations are not taken into account, we are counting twelve events
in X = 3 that actually are occurring in X = 2.
Results of the Fleming & Harrington test for later times are exposed in Table 5.8.
If migrations are not taken in consideration survival curves in both samples are not
statistically diﬀerent (p-value p = 0.961). However the assumption of diﬀerences
between survival functions does hold with landmark estimates (p-value p = 0.024).
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ZW p-value
Kaplan & Meier 0 0.961
Landmark analysis 1.98 0.024
Table 5.8: Value of the ZW statistic of the Fleming & Harrington test for both
methodologies. Also the significance of the test is reported. While within the
landmark analysis framework proportional hazards assumption holds, for the
Kaplan & Meier estimates does not.
Figure 5.4 presents the set of diagnosis plots for checking the proportional hazards
assumption.
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Figure 5.4: Diagnosis plots for the proportional hazards assumption. Although
survival functions are statistically diﬀerent, in these plots proportional hazard
assumption does not seem to hold (see upper-left plot). On the other hand the
linear regression (upper-right plot) does not clearly fit. This behavior can be
also seen on the bottom plot where variability between hazard ratios estimates is
remarkable.
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In the upper-left plot it is not clear if proportional hazard condition holds. Apart
from the crossing registered around the day 200, after this time it is not sure if
proportional hazards takes place. Focusing on the highest times (from day 250 until
the end of the study) the linear regression does not fit as clearly as it did when
studying the death as outcome (r2 = 0.9588). From this linear regression we will
proceed computing the parameter of the Cox model as we did in the section before,
￿β = 0.120, CIα=0.05 = (−0.075, 0.315). (5.4)
The estimated parameter of the Cox model includes the zero value, which implies
that the hazard ratio estimated could be e￿β = e0 = 1. However due to the fact that
the Fleming & Harrington test lead us to the conclusion that survival estimates
are statistically diﬀerent this also leads to the conclusion that hazard rates are also
diﬀerent. So we will conclude setting that hazard rates are statistically diﬀerent
but proportional hazards assumption does not hold and consequently no hazard
ratio can be estimated when studying the first occurring event.

Chapter 6
Discussion, limitations and
further research
In this chapter we present an overall view of the results achieved during the study.
First section will be devoted to discuss the results achieved in the multivariate
model for the non-adherence and subsequently we will continue discussing the
results obtained with the landmark methodology. This study has some limitations
that will be discussed in the second section. This chapter will finish presenting the
possibilities on further research that this study enables for an upcoming research.
1 Discussion
We identify several risk factors when we model the non-adherence to treatment
by means of a multivariate logistic regression model. The most important factor is
presenting atrial fibrillation (￿OR = 2.268) which means that the fact of presenting
this co-morbility is a considerable risk factor for the adherence to treatment.
Another cardiac disease that the model includes as a risk factor for the adherence
is the fact of presenting heart failure (￿OR = 1.767). Apart from the cardiac
diseases we encounter the fact of presenting moderate/acute level of depression as
a risk factor at the time of being adherent (￿OR = 1.699). The unique sociological
variable that the model includes is the medical covering of the patient: the fact of
having a for-profit medical insurance is a protector factor for the non adherence in
comparison with those that have a non-profit medical insurance (￿OR = 0.220).
These results lead to the conclusion that the severity of the patient is explanatory
at the time to predict the non-adherence to treatment. Furthermore: the higher the
severity of the patient the higher the risk of being non-adherent to treatment. These
results are consistent with the results published on the literature [3, 4, 7]. Other
variables that the literature presents as risk factors such educational level, the fact
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of living alone or the fact of being immigrant; were not statistically significant
neither in the univariate analysis nor in the multivariate.
Conclusions on the performance of the final model is that it is well calibrated but
does not have a well behavior on the discrimination. The observed non-adherent
rates are the same that the expected ones in each cut performed by the Hosmer &
Lemeshow test (p-value, p = 0.7183 and r2 = 1 in Figure 3.2). This perfect match
between non adherent rates could be driven by the fact of having a low value of
cuts (G = 3). The fact of working with a logistic regression with only dichotomous
and a categorical variable, lead to register a low number of estimated probabilities
(see upper-left and upper-right plot in Figure 3.2) and therefore to the incapacity
of performing a high number of cuts. The desirable number of cuts for the Hosmer
& Lemeshow test is G = 10, if the model enables it [14].
On the other hand the low AUC value (AUC=0.585) leads us to the conclusion
that there is a lot of information outside the data set that could explain the
non adherence to treatment. In other words, our data does not store most of the
variability for explaining the non adherence to treatment. With this model we are
not capable to predict if patients will belong to the adherent or not adherent status
in a balanced way (see Table 3.8 with its discussion).
It has been argued that Kaplan & Meier drives to biased survival estimates when
stratifying by a covariate when group membership is defined during the follow-up of
the study. The second endpoint of the study was to built and apply the landmark
methodology which overcomes this problem. Two diﬀerent outcomes were studied:
the death and the first of the occurring events between death, stroke or acute
coronary syndrome.
The clinical hypothesis was that patients taking three pills had to have a better
prognostic than those taking two or less. Studying the Kaplan & Meier estimates
no diﬀerences between samples were found (p = 0.538 and p = 0.961 of the Fleming
& Harrington test for death and for the first occurring event, respectively). On the
other hand, when studying the landmark survival estimates, survival curves were
statistically diﬀerent for later times (p = 0.0004 and p = 0.024, respectively).
Proportional hazards assumption was checked in the Cox model performed. We
checked empirically via three diﬀerent diagnosis plots (see Section 4 in Chapter 4).
When studying death as outcome, proportional hazards assumption held and its
value was estimated (￿k = 1.256, CIα=0.05 = (1.067, 1.481)). When studying the first
occurring event as outcome, proportional hazards situation does not take place.
In our study we did not know in which precise moment migrations and censoring
happened. Due to this fact we created the four landmark points. However, if in
a study it is known the precise time when migrations and censoring occur, the
landmark methodology allows to apply the estimators (4.11) and (4.12) in any time
where they occur. Therefore, the landmark estimator can be applied as Kaplan
& Meier is applied: As a recurrent formula ∀ti ∈ [0, τ ], being τ the time of the
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follow-up.
2 Limitations and further research
This study presents several limitations. First of all the definition of the non-
adherence to treatment variable is controversial. Assessing adherence to treat-
ment asking patients whether they are still taking their medication is an approach
opened to bias and possible overestimation [2]. This article claims that, in a
PubMed search, seven studies assessed adherence by this way including 49,791
patients over a median follow-up of 14 months in patients who had experienced a
myocardial infarction. The adherence in these studies was 90%, CIα=0.05 = (87, 92),
which are similar values registered in our study (see Table 3.1). Other limitation
that this part of the study presents is that the data base available was from other
study designed for cardiology purposes. Therefore it mainly stores information
about the cardiac profile of the patient. As it is discussed in the section before,
this could have been a limitation at the time of assessing the non adherence to
treatment.
For ongoing research, the problem on discrimination could be avoided using a clas-
sification tree [19], which provides a less rigid tool for classifying. The drawback of
this technique is that results are less interpretable than the logistic regression ones,
which gives a score of having the outcome of interest.
For the landmark analysis endpoint an important limitation is the data base in
which methodology was applied. Recall that it stores patients from the baseline
data set that suﬀered at least one of these three events: death, stroke or acute
coronary syndrome. That is, we obviated all those patients that did not suﬀered
an event. Ongoing studies should take into account these patients at the time of
estimating survival functions and treat them as lost to follow-up censored patients.
This second part of the study allows a wide range of possibilities on further research.
First of all patients assigned with two pills at the baseline time, Z(0) = 2, were
patients that could present more health problems than those starting with three
pills, Z(0) = 3. Maybe to carry out a preliminary comparative analysis between
both samples would permit to understand the characteristics that make them
diﬀerent, if they exist. If some variables are distributed diﬀerently in both samples
a more accurate procedure could be to adjust both samples by these variables.
Oncoming studies can investigate thoroughly the proportional hazards model within
the landmark framework. In the present study only one covariate was taken into
account for the Cox model and therefore the estimation of the hazard ratio could
be achieved by the diagnose plots presented. If several covariates are introduced in
the model, two dimensional plots do not answer the question about if proportional
hazards is taking place. Therefore new tools on checking the proportional hazards
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assumption can be studied and developed.
Further research can also focus on the censoring pattern. For this study censoring
was treated as non-informative, that is independent of the random variable of the
time until the outcome. However, drugs prescribed in this study have an eﬀect on
arterial pressure and cardiac frequency and both variables have an eﬀect on the
enhancement of the patient. However it is known that these drugs also increase the
risk of suﬀering stroke or acute coronary syndrome. Therefore, maybe censoring
happens due to the fact of having suﬀered one of these events during the follow-up.
For instance if a patient experiences one of these events, maybe he or she could
quit the study for medical prescription or due to its concerning about these adverse
eﬀects. However censoring is not frequent in the data set studied and we suppose
that, if censoring was informative, it might not lead to bias when treated as non
informative.
An interesting door that this master thesis opens is the merging of the landmark
methodology and the competing risk framework due to the fact that both situations
are not unusual to appear together in a clinical study.

Appendix A
R programming code
In this appendix the R code developed for the second part of the study is presented.
The first section presents the code to estimate the survival functions within the
landmark methodology. Section 2 implements the Fleming & Harrington test for
later diﬀerences. Section 3 presents the code used to check the proportional hazards
assumption. Each section will be divided into two subsections: The program when
studying death as outcome and the program for the first occurring outcome.
1 Landmark estimations
1.1 Landmark estimation for death
No package was found in R which has implemented the landmark methodology.
Due to this fact a simple but eﬀective program was built for estimating survival
functions.
Two diﬀerent data frames were created: One for those patients starting with two
pills, Z(0) = 2, and another for those who started with three, Z(0) = 3. These
data frames are named death_Z2 and death_Z3, respectively. These data frames
consist on seven columns: the days were an event occurred (days_2,days_3),
individuals under risk in each time of event (n.risk_2,n.risk_3), the events
occurred (n.event_2,n.event_3), patients censored (Cens_2,Cens_3), mi-
grations from X = 2 to X = 3 (Z2toZ3_2,Z2toZ3_3), migrations from X = 3
to X = 2, (Z3toZ2_2,Z3toZ2_3) and the survival estimations (survival_2,
survival_3). The endings _2,_3 make reference at the fact of variables be-
longing to death_Z2 or death_Z3, respectively. Migrations and censoring are
counted at days 90, 180, 270 and 360. After these days there are the four landmark
points.
The algorithm consists on running the Kaplan & Meier estimator (K&M) between
landmark points and to apply the landmark correction at each landmark point.
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## Before the first landmark point (K&M)
k<-1
for(k in 2:11){
death_Z2$survival_2[k]<-
((death_Z2$n.risk_2[k]-death_Z2$n.event_2[k])/death_Z2$n.risk_2[k])*
death_Z2$survival_2[k-1]
}
k<-1
for(k in 2:11){
death_Z3$survival_3[k]<-
((death_Z3$n.risk_3[k]-death_Z3$n.event_3[k])/death_Z3$n.risk_3[k])*
death_Z3$survival_3[k-1]
}
## First landmark point,
death_Z2$survival_2[12]<-
((death_Z2$n.risk_2[12]-death_Z2$n.event_2[12])/death_Z2$n.risk_2[12])*
(((death_Z2$n.risk_2[12]-death_Z2$Z3toZ2_2[11])/death_Z2$n.risk_2[12])*
death_Z2$survival_2[11]+(death_Z2$Z3toZ2_2[11]/death_Z2$n.risk_2[12])*
death_Z3$survival_3[11])
death_Z3$survival_3[12]<-
((death_Z3$n.risk_3[12]-death_Z3$n.event_3[12])/death_Z3$n.risk_3[12])*
(((death_Z3$n.risk_3[12]-death_Z3$Z2toZ3_3[11])/death_Z3$n.risk_3[12])*
death_Z3$survival_3[11]+(death_Z3$Z2toZ3_3[11]/death_Z3$n.risk_3[12])*
death_Z2$survival_2[11])
## Before the second landmark point (K&M)
k<-1
for(k in 13:15){
death_Z2$survival_2[k]<-
((death_Z2$n.risk_2[k]-death_Z2$n.event_2[k])/death_Z2$n.risk_2[k])*
death_Z2$survival_2[k-1]
}
death_Z3$survival_3[13]<-
((death_Z3$n.risk_3[13]-death_Z3$n.event_3[13])/death_Z3$n.risk_3[13])*
death_Z3$survival_3[12]
## Second landmark point
death_Z2$survival_2[16]<-
((death_Z2$n.risk_2[16]-death_Z2$n.event_2[16])/death_Z2$n.risk_2[16])*
(((death_Z2$n.risk_2[16]-death_Z2$Z3toZ2_2[15])/death_Z2$n.risk_2[16])*
death_Z2$survival_2[15]+(death_Z2$Z3toZ2_2[15]/death_Z2$n.risk_2[16])*
death_Z3$survival_3[13])
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death_Z3$survival_3[14]<-
((death_Z3$n.risk_3[14]-death_Z3$n.event_3[14])/death_Z3$n.risk_3[14])*
(((death_Z3$n.risk_3[14]-death_Z3$Z2toZ3_3[13])/death_Z3$n.risk_3[14])*
death_Z3$survival_3[13]+(death_Z3$Z2toZ3_3[13]/death_Z3$n.risk_3[14])*
death_Z2$survival_2[15])
## Before the third landmark point (K&M)
k<-1
for(k in 17:25){
death_Z2$survival_2[k]<-
((death_Z2$n.risk_2[k]-death_Z2$n.event_2[k])/death_Z2$n.risk_2[k])*
death_Z2$survival_2[k-1]
}
death_Z3$survival_3[15]<-
((death_Z3$n.risk_3[15]-death_Z3$n.event_3[15])/death_Z3$n.risk_3[15])*
death_Z3$survival_3[14]
## Third landmark point
death_Z2$survival_2[26]<-
((death_Z2$n.risk_2[26]-death_Z2$n.event_2[26])/death_Z2$n.risk_2[26])*
(((death_Z2$n.risk_2[26]-death_Z2$Z3toZ2_2[25])/death_Z2$n.risk_2[26])*
death_Z2$survival_2[25]+(death_Z2$Z3toZ2_2[25]/death_Z2$n.risk_2[26])*
death_Z3$survival_3[15])
death_Z3$survival_3[16]<-
((death_Z3$n.risk_3[16]-death_Z3$n.event_3[16])/death_Z3$n.risk_3[16])*
(((death_Z3$n.risk_3[16]-death_Z3$Z2toZ3_3[15])/death_Z3$n.risk_3[16])*
death_Z3$survival_3[15]+(death_Z3$Z2toZ3_3[15]/death_Z3$n.risk_3[16])*
death_Z2$survival_2[25])
## Before the fourth landmark point (K&M)
k<-1
for(k in 27:28){
death_Z2$survival_2[k]<-
((death_Z2$n.risk_2[k]-death_Z2$n.event_2[k])/death_Z2$n.risk_2[k])*
death_Z2$survival_2[k-1]
}
death_Z3$survival_3[17]<-
((death_Z3$n.risk_3[17]-death_Z3$n.event_3[17])/death_Z3$n.risk_3[17])*
death_Z3$survival_3[16]
## Fourth landmark point
death_Z2$survival_2[29]<-
((death_Z2$n.risk_2[29]-death_Z2$n.event_2[29])/death_Z2$n.risk_2[29])*
(((death_Z2$n.risk_2[29]-death_Z2$Z3toZ2_2[28])/death_Z2$n.risk_2[29])*
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death_Z2$survival_2[28]+(death_Z2$Z3toZ2_2[28]/death_Z2$n.risk_2[29])*
death_Z3$survival_3[17])
death_Z3$survival_3[18]<-
((death_Z3$n.risk_3[18]-death_Z3$n.event_3[18])/death_Z3$n.risk_3[18])*
(((death_Z3$n.risk_3[18]-death_Z3$Z2toZ3_3[17])/death_Z3$n.risk_3[18])*
death_Z3$survival_3[17]+(death_Z3$Z2toZ3_3[17]/death_Z3$n.risk_3[18])*
death_Z2$survival_2[28])
## Last stretch (K&M)
k<-1
for(k in 30:34){
death_Z2$survival_2[k]<-
((death_Z2$n.risk_2[k]-death_Z2$n.event_2[k])/death_Z2$n.risk_2[k])*
death_Z2$survival_2[k-1]
}
k<-1
for(k in 19:34){
death_Z3$survival_3[k]<-
((death_Z3$n.risk_3[k]-death_Z3$n.event_3[k])/death_Z3$n.risk_3[k])*
death_Z3$survival_3[k-1]
}
1.2 Landmark estimation for the first event between death,
stroke and acute coronary syndrome
Two diﬀerent data frames were created: One for those starting with two pills,
Z(0) = 2, an the other for those who started with three, Z(0) = 3. These data
frames are named ce_Z2 and ce_Z3, respectively. These data frames consist
on six columns: the days were an event occurred (days_ce_2,days_ce_3),
individuals under risk in each time of event (n.risk_ce_2,n.risk_ce_3), the
events occurred (n.event_ce_2,n.event_ce_3), migrations from X = 2 to
X = 3 (Z2toZ3_ce_2, Z2toZ3_ce_3), migrations from X = 3 to X = 2,
(Z3toZ2_ce_2,Z3toZ2_ce_3) and the survival estimations (survival_ce_2,
survival_ce_3). The endings _2,_3 make reference at the fact of variables
belonging to ce_Z2 or ce_Z3, respectively. Migrations are counted at days 90,
180, 270 and 360. After these days there are the four landmark points.
The algorithm consists on running the Kaplan & Meier estimator (K&M) between
landmark points and to apply the landmark correction at each landmark point.
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## Before the first landmark point (K&M)
k<-1
for(k in 2:20){
ce_Z2$survival_ce_2[k]<-
((ce_Z2$n.risk_ce_2[k]-ce_Z2$n.event_ce_2[k])/ce_Z2$n.risk_ce_2[k])*
ce_Z2$survival_ce_2[k-1]
}
k<-1
for(k in 2:24){
ce_Z3$survival_ce_3[k]<-
((ce_Z3$n.risk_ce_3[k]-ce_Z3$n.event_ce_3[k])/ce_Z3$n.risk_ce_3[k])*
ce_Z3$survival_ce_3[k-1]
}
## First landmark point
ce_Z2$survival_ce_2[21]<-
((ce_Z2$n.risk_ce_2[21]-ce_Z2$n.event_ce_2[21])/ce_Z2$n.risk_ce_2[21])*
(((ce_Z2$n.risk_ce_2[21]-ce_Z2$Z3toZ2_ce_2[20])/ce_Z2$n.risk_ce_2[21])*
ce_Z2$survival_ce_2[20]+(ce_Z2$Z3toZ2_ce_2[20]/ce_Z2$n.risk_ce_2[21])*
ce_Z3$survival_ce_3[24])
ce_Z3$survival_ce_3[25]<-
((ce_Z3$n.risk_ce_3[25]-ce_Z3$n.event_ce_3[25])/ce_Z3$n.risk_ce_3[25])*
(((ce_Z3$n.risk_ce_3[25]-ce_Z3$Z2toZ3_ce_3[24])/ce_Z3$n.risk_ce_3[25])*
ce_Z3$survival_ce_3[24]+(ce_Z3$Z2toZ3_ce_3[24]/ce_Z3$n.risk_ce_3[25])*
ce_Z2$survival_ce_2[20])
## Before the second landmark point (K&M)
k<-1
for(k in 22:32){
ce_Z2$survival_ce_2[k]<-
((ce_Z2$n.risk_ce_2[k]-ce_Z2$n.event_ce_2[k])/ce_Z2$n.risk_ce_2[k])*
ce_Z2$survival_ce_2[k-1]
}
k<-1
for(k in 26:33){
ce_Z3$survival_ce_3[k]<-
((ce_Z3$n.risk_ce_3[k]-ce_Z3$n.event_ce_3[k])/ce_Z3$n.risk_ce_3[k])*
ce_Z3$survival_ce_3[k-1]
}
## Second landmark point
ce_Z2$survival_ce_2[33]<-
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((ce_Z2$n.risk_ce_2[33]-ce_Z2$n.event_ce_2[33])/ce_Z2$n.risk_ce_2[33])*
(((ce_Z2$n.risk_ce_2[33]-ce_Z2$Z3toZ2_ce_2[32])/ce_Z2$n.risk_ce_2[33])*
ce_Z2$survival_ce_2[32]+(ce_Z2$Z3toZ2_ce_2[32]/ce_Z2$n.risk_ce_2[33])*
ce_Z3$survival_ce_3[33])
ce_Z3$survival_ce_3[34]<-
((ce_Z3$n.risk_ce_3[34]-ce_Z3$n.event_ce_3[34])/ce_Z3$n.risk_ce_3[34])*
(((ce_Z3$n.risk_ce_3[34]-ce_Z3$Z2toZ3_ce_3[33])/ce_Z3$n.risk_ce_3[34])*
ce_Z3$survival_ce_3[32]+(ce_Z3$Z2toZ3_ce_3[33]/ce_Z3$n.risk_ce_3[34])*
ce_Z2$survival_ce_2[32])
## Before the third landmark point (K&M)
k<-1
for(k in 34:49){
ce_Z2$survival_ce_2[k]<-
((ce_Z2$n.risk_ce_2[k]-ce_Z2$n.event_ce_2[k])/ce_Z2$n.risk_ce_2[k])*
ce_Z2$survival_ce_2[k-1]
}
k<-1
for(k in 35:37){
ce_Z3$survival_ce_3[k]<-
((ce_Z3$n.risk_ce_3[k]-ce_Z3$n.event_ce_3[k])/ce_Z3$n.risk_ce_3[k])*
ce_Z3$survival_ce_3[k-1]
}
## Third landmark point
ce_Z2$survival_ce_2[50]<-
((ce_Z2$n.risk_ce_2[50]-ce_Z2$n.event_ce_2[50])/ce_Z2$n.risk_ce_2[50])*
(((ce_Z2$n.risk_ce_2[50]-ce_Z2$Z3toZ2_ce_2[49])/ce_Z2$n.risk_ce_2[50])*
ce_Z2$survival_ce_2[49]+(ce_Z2$Z3toZ2_ce_2[49]/ce_Z2$n.risk_ce_2[50])*
ce_Z3$survival_ce_3[37])
ce_Z3$survival_ce_3[38]<-
((ce_Z3$n.risk_ce_3[38]-ce_Z3$n.event_ce_3[38])/ce_Z3$n.risk_ce_3[38])*
(((ce_Z3$n.risk_ce_3[38]-ce_Z3$Z2toZ3_ce_3[37])/ce_Z3$n.risk_ce_3[38])*
ce_Z3$survival_ce_3[37]+(ce_Z3$Z2toZ3_ce_3[37]/ce_Z3$n.risk_ce_3[38])*
ce_Z2$survival_ce_2[49])
## Before the fourth landmark point (K&M)
k<-1
for(k in 51:61){
ce_Z2$survival_ce_2[k]<-
((ce_Z2$n.risk_ce_2[k]-ce_Z2$n.event_ce_2[k])/ce_Z2$n.risk_ce_2[k])*
ce_Z2$survival_ce_2[k-1]
}
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k<-1
for(k in 39:41){
ce_Z3$survival_ce_3[k]<-
((ce_Z3$n.risk_ce_3[k]-ce_Z3$n.event_ce_3[k])/ce_Z3$n.risk_ce_3[k])*
ce_Z3$survival_ce_3[k-1]
}
## Fourth landmark point
ce_Z2$survival_ce_2[62]<-
((ce_Z2$n.risk_ce_2[62]-ce_Z2$n.event_ce_2[62])/ce_Z2$n.risk_ce_2[62])*
(((ce_Z2$n.risk_ce_2[62]-ce_Z2$Z3toZ2_ce_2[61])/ce_Z2$n.risk_ce_2[62])*
ce_Z2$survival_ce_2[61]+(ce_Z2$Z3toZ2_ce_2[61]/ce_Z2$n.risk_ce_2[62])*
ce_Z3$survival_ce_3[41])
ce_Z3$survival_ce_3[42]<-
((ce_Z3$n.risk_ce_3[42]-ce_Z3$n.event_ce_3[42])/ce_Z3$n.risk_ce_3[42])*
(((ce_Z3$n.risk_ce_3[42]-ce_Z3$Z2toZ3_ce_3[41])/ce_Z3$n.risk_ce_3[42])*
ce_Z3$survival_ce_3[41]+(ce_Z3$Z2toZ3_ce_3[41]/ce_Z3$n.risk_ce_3[42])*
ce_Z2$survival_ce_2[61])
## Last stretch (K&M)
k<-1
for(k in 63:70){
ce_Z2$survival_ce_2[k]<-
((ce_Z2$n.risk_ce_2[k]-ce_Z2$n.event_ce_2[k])/ce_Z2$n.risk_ce_2[k])*
ce_Z2$survival_ce_2[k-1]
}
k<-1
for(k in 43:70){
ce_Z3$survival_ce_3[k]<-
((ce_Z3$n.risk_ce_3[k]-ce_Z3$n.event_ce_3[k])/ce_Z3$n.risk_ce_3[k])*
ce_Z3$survival_ce_3[k-1]
}
2 Fleming & Harrington test
For the Fleming & Harrington test we worked with the previous data frames. The
FHtestrcc function implemented in the FHtest package enables to run the
Fleming & Harrington test for Surv objects created by the survival package.
Due to the fact that the survival estimates are computed outside this packages we
built a program which estimates the ZW statistic.
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2.1 Fleming & Harrington test for death
## 1.1) Weights
Surv_weights<-survfit(Surv(days, exitus=="1,00")~1, BD_death)
q<-1 ## later differences
Weights<-(1-summary(Surv_weights)$surv)^q
length(Weights)
## 1.2) Data frame preparation
## To which group estimates belong,
death_Z2$Group<-"C"
death_Z3$Group<-"T"
colnames(death_Z2)<-c("time","n.risk","n.event","cens","Z2toZ3","Z3toZ2",
"survival")
colnames(death_Z3)<-c("time","n.risk","n.event","cens","Z2toZ3","Z3toZ2",
"survival")
FHTest<-merge(death_Z2, death_Z3,all=T)
FHTest_1<-FHTest[with(FHTest, order(time)),]
## We do not need information about migration or censoring,
FHTest_2<-FHTest_1[,-c(4,5,6)]
colnames(FHTest_2)<-c("time","n.risk","n.event","survival","Group")
## 1.2.1) Computation of the n_i,d_i,n_i2,n_i3 parameters,
summary(Surv_weights)
d_i<-summary(Surv_weights)$n.event
length(d_i)
n_i<-summary(Surv_weights)$n.risk
length(n_i)
FHTest_2$d_iT<-ifelse(FHTest_2$Group=="T",FHTest_2$n.event,0)
FHTest_2$d_iC<-ifelse(FHTest_2$Group=="C",FHTest_2$n.event,0)
FHTest_2$n_iT<-ifelse(FHTest_2$Group=="T",FHTest_2$n.risk,0)
FHTest_2$n_iC<-ifelse(FHTest_2$Group=="C",FHTest_2$n.risk,0)
## 1.2.2) We restructure the data frame due to some ties between
groups,
FHTest_2[1,]$n_iT<-65
FHTest_2[36,]$d_iC<-1
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FHTest_2[36,]$n_iC<-57
FHTest_2[50,]$d_iC<-1
FHTest_2[50,]$n_iC<-41
FHTest_2[53,]$d_iC<-1
FHTest_2[53,]$n_iC<-40
FHTest_3<-FHTest_2[-c(2,37,51,54),]
FHTest_4<-FHTest_3[-1,]
FHTest_4$n_i<-n_i
FHTest_4$d_i<-d_i
## 1.3) Z_W computation,
### Numerator
Z_Numerator<-sum(Weights*(FHTest_4$d_iC-FHTest_4$n_iC*(FHTest_4$d_i/n_i)))
### Denominator
Z_Denominator<-sum((Weights)^2*FHTest_4$n_iC*(1-FHTest_4$n_iC/FHTest_4$n_i)*
(n_i-FHTest_4$d_i)*FHTest_4$d_i/(n_i*(n_i-1)))
### Fleming & Harrington test
Z<-Z_Numerator/Z_Denominator
Z
1-pnorm(Z,mean=0, sd=1)
2.2 Fleming & Harrington test for the first event between
death, stroke and acute coronary syndrome
## 1.1) Weights
Surv_weights<-survfit(Surv(days)~1, BD_CE)
q<-1 ## later differences
Weights<-(1-summary(Surv_weights)$surv)^q
length(Weights)
## 1.2) Data frame preparation
## To which group estimates belong,
ce_Z2$Group<-"C"
ce_Z3$Group<-"T"
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colnames(ce_Z2)<-c("time","n.risk","n.event","Z2toZ3","Z3toZ2",
"survival","Group")
colnames(ce_Z3)<-c("time","n.risk","n.event","Z2toZ3","Z3toZ2",
"survival","Group")
FHTest<-merge(ce_Z2, ce_Z3,all=T)
FHTest_1<-FHTest[with(FHTest, order(time)),]
## We do not need information about migration or censoring,
FHTest_2<-FHTest_1[,-c(4,5)]
## 1.2.1) Computation of the n_i,d_i,n_i2,n_i3 parameters,
summary(Surv_weights)
d_i<-summary(Surv_weights)$n.event
length(d_i)
n_i<-summary(Surv_weights)$n.risk
length(n_i)
FHTest_2$d_iT<-ifelse(FHTest_2$Group=="T",FHTest_2$n.event,0)
FHTest_2$d_iC<-ifelse(FHTest_2$Group=="C",FHTest_2$n.event,0)
FHTest_2$n_iT<-ifelse(FHTest_2$Group=="T",FHTest_2$n.risk,0)
FHTest_2$n_iC<-ifelse(FHTest_2$Group=="C",FHTest_2$n.risk,0)
## 1.2.2) We restructure the data frame due to some ties between
groups
FHTest_2[1,]$n_iT<-65
FHTest_2[3,]$d_iT<-2
FHTest_2[3,]$n_iT<-65
FHTest_2[5,]$d_iT<-1
FHTest_2[5,]$n_iT<-63
FHTest_2[30,]$d_iC<-1
FHTest_2[30,]$n_iC<-51
FHTest_2[32,]$d_iC<-1
FHTest_2[32,]$n_iC<-50
FHTest_2[78,]$d_iC<-1
FHTest_2[78,]$n_iC<-26
FHTest_2[111,]$d_iT<-1
FHTest_2[111,]$n_iT<-3
FHTest_2[115,]$d_iT<-1
FHTest_2[115,]$n_iT<-1
FHTest_3<-FHTest_2[-c(2,4,6,31,33,79,112,116),]
FHTest_4<-FHTest_3[-1,]
nrow(FHTest_4)
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length(n_i)
FHTest_4$n_i<-n_i
FHTest_4$d_i<-d_i
## 1.3) Z_W computation,
### Numerator
Z_Numerator<-sum(Weights*(FHTest_4$d_iC-FHTest_4$n_iC*(FHTest_4$d_i/n_i)))
### Denominator
Z_Denominator<-sum((Weights)^2*FHTest_4$n_iC*(1-FHTest_4$n_iC/FHTest_4$n_i)*
(n_i-FHTest_4$d_i)*FHTest_4$d_i/(n_i*(n_i-1)))
### Fleming & Harrington test
Z<-Z_Numerator/Z_Denominator
Z
1-pnorm(Z,mean=0, sd=1)
3 Proportional hazards diagnosis
For checking the proportional hazards assumption three diﬀerent plots were per-
formed (see Section 4 in Chapter 4). First of all we proceed computing the cu-
mulative hazards and following we proceed estimating the cumulative hazard in
equidistant points in time, ti for i = 1, ..., l for both samples.
3.1 Proportional hazards diagnosis for death
## 1) We compute the cumulative hazards
death_Z2$cum_haz<--log(death_Z2$survival)
death_Z3$cum_haz<--log(death_Z3$survival)
## 2) We compute the cumulative hazards in equidistant t_i, i=1,...,l.
We do it for times t=50 until 450 with 50 days lapse.
time<-seq(50,450, by=50)
## X=2
m2<-double()
n2<-double()
hazards2<-double()
for(j in 1:length(time)){
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for(k in 1:(nrow(death_Z2)-1)){
if((death_Z2$time[k]<50*j & death_Z2$time[k+1]>50*j)|
death_Z2$time[k]==50*j){
m2[k]<-(death_Z2$cum_haz[k+1]-death_Z2$cum_haz[k])/
(death_Z2$time[k+1]-death_Z2$time[k])
n2[k]<-death_Z2$cum_haz[k]-m2[k]*death_Z2$time[k]
hazards2[k]<-m2[k]*50*j+n2[k]
}
}
}
## X=3
m3<-double()
n3<-double()
hazards3<-double()
for(j in 1:length(time)){
for(k in 1:(nrow(death_Z3)-1)){
if((death_Z3$time[k]<50*j & death_Z3$time[k+1]>50*j)|
death_Z3$time[k]==50*j){
m3[k]<-(death_Z3$cum_haz[k+1]-death_Z3$cum_haz[k])/
(death_Z3$time[k+1]-death_Z3$time[k])
n3[k]<-death_Z3$cum_haz[k]-m3[k]*death_Z3$time[k]
hazards3[k]<-m3[k]*50*j+n3[k]
}
}
}
hazard2_noNA<-hazards2[!is.na(hazards2)]
append(hazards3[!is.na(hazards3)],0.18875288,2)
hazard3_noNA<-append(append(hazards3[!is.na(hazards3)],0.18875288,2),
0.40327639,6)
## 3) We plot the three different diagnosis Figures
layout(matrix(c(1,2,3,3),2,2,byrow=T))
###cumulative hazards versus time
plot(death_Z2$cum_haz~death_Z2$time, xlab="time (days)",
ylab=expression(Lambda(t,X)),type="l", col=3,las=1, cex.axis=0.8,
cex.lab=0.9)
lines(death_Z3$cum_haz~death_Z3$time, col=4, type="l")
legend("bottomright", cex=.9,c(expression(X==2), expression(X==3)),
col=c(3,4), lty=1, lwd=1)
### log hazards linear regression in t_i, i=1,...,l.
lm(log(hazard2_noNA)~log(hazard3_noNA))
confint(lm(log(hazard2_noNA)~log(hazard3_noNA)))
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summary(lm(log(hazard2_noNA)~log(hazard3_noNA)))
plot(log(hazard2_noNA)~log(hazard3_noNA),
xlab=expression(log(Lambda(t,X==3))),
ylab=expression(log(Lambda(t,X==2))) ,xlim=c(-2.5,0),
ylim=c(-2.5,1),las=1, cex.axis=0.8, cex.lab=0.9)
abline(a=lm(log(hazard2_noNA)~log(hazard3_noNA))$coeff[1],
b=lm(log(hazard2_noNA)~log(hazard3_noNA))$coeff[2])
legend("bottomright", expression(r^2==0.9815), cex=.9)
### hazard ratios k_i, t_i=1,...,l.
plot(hazard2_noNA/hazard3_noNA~time,xlab="time (days)",
ylab=expression(Lambda(t,X==2)/Lambda(t,X==3)) ,ylim=c(1,1.5),
type="p",las=1, cex.axis=0.8, cex.lab=0.9)
abline(a=median(hazard2_noNA/hazard3_noNA),b=0, col="red", lty=2)
title(main="Proportional hazards diagnosis", outer=T, line=-1)
3.2 Proportional hazards diagnosis for the first event be-
tween death, stroke and acute coronary syndrome
## 1) We compute the cumulative hazards
ce_Z2$Cum_Haz<--log(ce_Z2$survival)
ce_Z3$Cum_Haz<--log(ce_Z3$survival)
## 2) We compute the cumulative hazards in equidistant t_i, i=1,...,l.
We do not observe proportionality until time=250 days. We do it from
250 to 450 with 40 days lapse.
timeB<-seq(250,450, by=40)
# X=2
m2B<-double()
n2B<-double()
hazards2B<-double()
for(j in 1:length(timeB)){
for(k in 1:(nrow(ce_Z2)-1)){
if((ce_Z2$time[k]<(250+40*(j-1)) & ce_Z2$time[k+1]>(250+40*(j-1)))|
ce_Z2$time[k]==(250+40*(j-1))){
m2B[k]<-(ce_Z2$Cum_Haz[k+1]-ce_Z2$Cum_Haz[k])/
ce_Z2$time[k+1]-ce_Z2$time[k])
n2B[k]<-ce_Z2$Cum_Haz[k]-m2B[k]*ce_Z2$time[k]
hazards2B[k]<-m2B[k]*(250+40*(j-1))+n2B[k]
}
}
}
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# X=3
m3B<-double()
n3B<-double()
hazards3B<-double()
for(j in 1:length(timeB)){
for(k in 1:(nrow(ce_Z3)-1)){
if((ce_Z3$time[k]<(250+40*(j-1)) & ce_Z3$time[k+1]>(250+40*(j-1)))|
ce_Z3$time[k]==(250+40*(j-1))){
m3B[k]<-(ce_Z3$Cum_Haz[k+1]-ce_Z3$Cum_Haz[k])/
(ce_Z3$time[k+1]-ce_Z3$time[k])
n3B[k]<-ce_Z3$Cum_Haz[k]-m3B[k]*ce_Z3$time[k]
hazards3B[k]<-m3B[k]*(250+40*(j-1))+n3B[k]
}
}
}
hazard2_ceB_noNA<-hazards2B[!is.na(hazards2B)]
hazard3_ceB_noNA<-hazards3B[!is.na(hazards3B)]
## 3) We plot the three different diagnosis Figures
layout(matrix(c(1,2,3,3),2,2,byrow=T))
### hazards versus
plot(ce_Z2$Cum_Haz~ce_Z2$time, xlab="time (days)",
ylab=expression(Lambda(t,X)),type="l", col=3,las=1, cex.axis=0.9,
cex.lab=1)
lines(ce_Z3$Cum_Haz~ce_Z3$time, col=4, type="l")
legend("bottomright", cex=1,c(expression(X==2), expression(X==3)),
col=c(3,4), lty=1, lwd=1)
### log hazards linear regression in t_i, i=1,...,l.
lm(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA))
confint(lm(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA)))
summary(lm(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA)))
lm(log(hazard3_ceB_noNA)~log(hazard2_ceB_noNA))
summary(lm(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA)))
plot(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA),
xlab=expression(log(Lambda(t,X==3))),
ylab=expression(log(Lambda(t,X==2))),las=1, cex.axis=0.9, cex.lab=1)
abline(a=lm(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA))$coeff[1],
b=lm(log(hazard2_ceB_noNA)~log(hazard3_ceB_noNA))$coeff[2])
legend("bottomright", expression(r^2==9588), cex=1)
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### hazard ratios k_i, t_i=1,...,l.
plot(hazard2_ceB_noNA/hazard3_ceB_noNA~timeB,xlab="time (days)",
ylab=expression(Lambda(t,X==2)/Lambda(t,X==3)), type="p",las=1,
cex.axis=0.8, cex.lab=0.9)
abline(a=median(hazard2_ceB_noNA/hazard3_ceB_noNA),b=0, col="red", lty=2)
title(main="Proportional hazards diagnosis", outer=T, line=-2)
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